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Abstract 
Notch signalling is a highly conserved pathway that is important in the 
developmental processes that control cell differentiation and cell fates. This 
canonical pathway involves binding of a transmembrane ligand in one cell to the 
extraceullular domain of a transmembrane Notch receptor in an adjacent cell. 
Ligand binding triggers two sequential proteolytic cleavages that shed a Notch 
intracellular domain (NICD). This is followed by translocation of NICD to the 
nucleus where it interacts with a transcription factor CSL and forms an 
activated Notch transcription complex, which induces the transcription of Notch 
target genes.  
Abnormal expression or mutations in the different components of the pathway 
are associated with a number of diseases and cancers. An enhanced activity of 
Notch signalling resulting from a mutation in the extracellular domain is 
implicated in the progression of T-acute lymphoblastic leukaemia (T-ALL). 
Several therapeutic agents have been developed to target the Notch signalling 
pathway such as, γ-secretase inhibitors, antibodies targeting different regions of 
the Notch receptor and recently a synthetic stapled peptide, which was found to 
inhibit the formation of the transcription complex. The current inhibitors have 
their own disadvantages including lack of selectivity, cost of goods and delivery 
to the target. Thus, a more selective approach to target downstream protein-
protein interactions by small molecules would provide an attractive approach to 
the design of new therapeutic agents that target this pathway. Here I report a 
fragment-based approach to target the ankyrin domain, a historically known but 
challenging, often-considered “undruggable” target.  
In this dissertation I describe the application of various biophysical and 
computational approaches to find, characterise and design compounds. The 
initial screening of a commercial fragment-library exploited a fluorescent-based 
thermal shift assay that identified 36 fragment hits. Some of the fragments were 
kinetically characterised by Surface Plasmon Resonance (SPR) and their 
affinities were found to be in the millimolar range. Several attempts at soaking 
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and co-crystallising the fragments in the ankyrin domain crystal resulted in only 
two successful crystal structures that clearly define the positions of the 
fragments and their interactions with the ankyrin domain. One fragment binds 
to a pre-defined hotspot residue at the interface between the ankyrin domain and 
CSL. The other fragment is located at the interface between the ankyrin domain 
and Mastermind (MAML). The structural and kinetic data assisted the design of 
larger compounds with more extensive interactions using drug design software 
such as SPROUT and a docking program (GOLD). However, the optimised 
fragments did not show much improvement in affinity underlying the difficulty 
of flat protein-protein interface. The results reported here show the first 
structures of small molecules binding to the ankyrin domain of Notch1 receptor  
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Chapter 1 
 
` Introduction 
The development of a single cell into a whole organism involves multiple rounds 
of cell division. The Notch pathway is one of several that enable cell 
communication during this process. The cell responses are influenced by the 
intensity of the signal and crosstalk with other signalling pathways.  
A notch in the wings of Drosophila melanogaster was first noticed by John 
Dexter in 1914 (Dexter, 1914). Soon after Thomas Morgan identified alleles of 
the gene in 1917 (Morgan, 1917) but the Notch gene was not itself identified in 
Drosophila until the 1980’s (Wharton et al., 1985; Kidd et al., 1986). Since then it 
has became evident that the Notch pathway is highly conserved and regulates a 
wide range of developmental processes, as demonstrated by extensive loss- and 
gain-of- function mutational experiments in various organisms. Indeed, the 
Notch pathway has provided a good area to investigate various functional, 
genetic, and structural aspects of a major signalling pathway. Understanding the 
defects and abnormalities associated with the signalling events has assisted in 
rationalising different treatment regimens.  
1.1 Biological significance of Notch signalling 
There are different mechanisms by which Notch can regulate cell fates; an 
important mechanism is lateral inhibition, in which equivalent cells can equally 
express both Notch receptors and ligands (Bray et al., 1998). However, subtle 
changes which are amplified by feedback loops will activate the expression of 
Notch receptor more than the ligand in one cell. This cell becomes the cell 
signalling cell whereas neighbouring cells become the receiving cells. Notch 
signalling cells remain undifferentiated and the neighbouring receiving cells 
adopt a different fate (Bray et al., 1998).  
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Notch signalling modulates many biological processes such as apoptosis, cell 
regulation, and lineage decisions during embryonic development. Notch plays an 
important role in vascular development in the human embryo. In endothelial 
cells, Notch receptors (Notch1, Notch2, and Notch4) are expressed, whereas in 
vascular smooth cells only Notch3 is expressed (Joutel et al., 2000; Lindner et al., 
2001; Villa et al., 2001). Notch signalling is also involved in CNS development by 
inhibiting neuronal differentiation. Knockout studies of Notch components cause 
precocious neuronal differentiation (Ishibashi et al., 1995; de la Pompa et al., 
1997; Hatakeyama et al., 2004).  
1.2 The components of Notch pathway 
a) Notch receptor: There are four Notch receptors in the mammalian signalling 
pathway: Notch1, Notch2, Notch3, Notch4.  
b) Notch ligands: The ligands are single transmembrane proteins and they are 
members of the (Delta, Serrate, Lag2) DSL family. The five mammalian ligands 
include two Jagged (Jagged1 and Jagged2) and three Delta (Delta-like-1, Delta-
like-3 and Delta-like-4) family proteins. 
 
c) DNA-binding proteins: These are the core of the transcriptional activation 
complex. They are known as CSL which is a collective name for C-promoter-
binding factor in mammals (known as CBF-1 or RBP-J), Supressor of Hairless 
Su(H) in Drosophila melanogaster and Lag-1 in Caenorhabditis elegans.  
 
d) Target genes:  Some Notch genes have been identified which participate in 
developmental processes. In Drosophila the Hairy/Enhancer of Split family genes 
were described as the direct Notch target genes. In mammals, Hes1, Hes5, Hes7 
and a subfamily of Hes (He1, Hey2, HeyL) were activated by Notch signalling. 
These are basic helix-loop-helix (bHLH) protein transcription factors that are 
involved in cell fate suppression. 
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1.3 The architecture of the Notch receptor 
The Notch receptor is a transmembrane receptor formed of extracellular and 
intracellular regions (Figure 1.2). 
a) The extracellular region: 
The extracellular region is composed mainly of 36 EGF-like (Epidermal Growth 
Factor-like) tandem repeats, a characteristic to the Notch family. Each repeat is 
a globular domain, consisting of 40 amino acids containing six cysteine residues 
that form three conserved disulphide bonds (Wharton et al., 1985). The role of 
the EGF-like repeats has been investigated by extensive deletion mutagenesis 
studies in Drosophila melanogaster. These studies revealed that the repeats 11 
and 12 are both important and sufficient to mediate interactions with the ligand 
Delta (Rebay et al., 1991). Similar studies were conducted on human Notch1 that 
concluded that the EGF-like repeat 12, and not repeats 11 or 13, was important 
for ligand binding (Cordle et al., 2008). 
 
The Notch receptor function is modulated through its EGF-like repeats by 
posttranslational modification. Fucose is transferred to serine and threonine 
residues in the conserved region of EGF-like repeats by O-fucosyl transferase1 
(Okajima & Irvine, 2002). This is followed by adding N-acetylglucosamine by 
fucose β-1,3-N-acetylglucosaminyltransferase (Panin et al., 1997; Bruckner et al., 
2000; Moloney et al., 2000) 
 
b) The negative regulatory region 
The negative regulatory region (NRR) consists of 3 cystine-rich Lin12-Notch (LN) 
repeats followed by a hetero-dimerisation region.  
The intracellular region 
The intracellular domain is composed of RAM region (RBPJκ-associated 
molecule region), 7 characterstic ankyrin repeats, transactivating domain and 
PEST domain.  
4 
 
The RAM region is natively unstructured in solution as was shown by 
biophysical studies (Nam et al., 2003). There have been speculations about the 
role of RAM in human. However, it is thought to help in docking the ankyrin 
domain correctly, by interacting first with the CSL and so increasing the local 
concentration of the ankyrin domain to bind to CSL (Friedman et al., 2008; 
Gordon et al., 2008). 
 
The ankyrin domain 
 
The ankyrin repeats have a conserved secondary and tertiary structure. Each 
repeat is composed of 33 amino acid residues, arranged in two antiparallel α-
helices connected by a short loop. The α-helices in each repeat are connected to 
helices of the adjacent repeat in a head-to-tail manner by a β-hairpin structure 
which is oriented perpendicular to the helices. This gives the ankyrin domain an 
L-shape in cross section. The ankyrin domain is a modular repeat protein which 
makes it impossible to be stabilised by direct interactions far apart in the 
squence – so called long-range interactions. Instead, the repeats are stabilised by 
intra- and inter-repeat hydrophobic and hydrogen-bond interactions. The repeats 
are packed against each other with the inner helices being shorter than the outer 
helices. The terminal or capping repeats are polar and solvent accessible.  
 
The ankyrin domain was thought to consist of six repeats, but recent studies 
confirmed the presence of an additional seventh repeat (Zweifel & Barrick, 2001; 
Ehebauer, 2005). The first repeat is partially folded and it assumes a regular 
ankyrin fold when it forms a complex with CSL and MAML (Zweifel 2003; 
Ehebauer 2005; Nam 2006). As a result of the repeat architecture of the ankyrin 
domain, it adopts a curved and concave structure. 
 
It has been reported recently that the ankyrin domain undergoes hydroxylation 
at residue Asn1945 by factor inhibiting hypoxia-inducing factor (FIH) (Coleman 
et al., 2007). Post-translational hydroxylation of intracellular proteins is a rare 
event. Hydroxylation of the ankyrin domain does not affect the formation of the 
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Notch ternary complex as hydroxylation involves residues which are distal to 
any protein-protein interfaces. This hydroxylation may not affect the Notch 
signalling directly but it is thought that the hydroxylated ankyrin domain may 
regulate (hypoxia-inducible factor) HIF signalling (Coleman et al., 2007). 
Crystallographic analysis suggested that the ankyrin domain might undergo a 
major conformational change to bind to FIH. However, this was based on the 
structure of a short ankyrin peptide in an ankyrin-FIH complex, which does not 
correctly reflect the exact interaction in solution (Coleman et al., 2007). On the 
other hand, biophysical studies using circular dichroism (CD) spectroscopy and 
differential scanning calorimetry experiments showed that some ankyrin domain 
repeats may appear more flexible than revealed in a frozen crystallographic state 
(Bradley & Barrick, 2005). 
 
The repeat structure of the ankyrin domain provides a scaffold for protein-
protein interactions with various protein partners. It interacts with a number of 
proteins involved in the Notch pathway, including Deltex through the first five 
repeats in Drosophila. Deltex appears to be a positive regulator of Notch 
signalling (Matsuno et al., 1995). In mammals on the other hand, the 
mammalian Deltex acts as an antagonist of Notch signalling (Diederich et al., 
1994). The ankyrin domain also interacts with p300 (Oswald et al., 2001). The 
histone acetyltransferases, PCAF and GCN5 (Kurooka et al., 2000), interact with 
the ankyrin domain, possibly playing a role in the RBP-J-mediated 
transactivation of the intracellular domain of Notch. The ability of the ankyrin 
domain to bind to different targets could be due to the fact that it does not 
recognise specific sequences of targets or motifs, but instead binding involves 
discontinuous epitopes across the ankyrin molecule.  
 
The stability and folding of the ankyrin domain have been studied extensively. 
Although it was originally thought that the ankyrin domain would unfold in a 
multistate manner involving a population of intermediates, energetic studies 
revealed that it folds cooperatively in a two-state manner (Bradely & Barrick, 
2006). Thermodynamic studies on Drosophila Notch ankyrin domain revealed 
6 
 
that the seventh repeat contributes more to the stability of the whole ankyrin 
domain than repeats six and five (Bradely & Barrick, 2002). 
 
1.4 The Notch CSL-dependant signalling pathway 
 
The Notch receptor is synthesised in the endoplasmic reticulum as a single-pass 
transmembrane protein. The single polypeptide is cleaved at S1 site by proteases 
of the furin family after being transported to the Golgi network (Logeat et al., 
1998) and forms a “heterodimer” receptor composed of extracellular region 
involved in ligand binding and an intracellular region responsible for membrane-
tethered signal transduction.  
 
Ligands of the DSL (Delta, Serrate, Lag2) family in one cell interact with the 
extracellular domain of Notch receptor in an adjacent cell. This results in two 
sequential cleavage processes; the first occurs at the S2 site by a member of the 
ADAM family of metalloproteases (Brou et al., 2000). This is followed by a second 
cleavage at the S3 site by the γ-secretase activity of the Presenilin-Nicastrin-
Aph1-Pen2 protein complex (Struhl et al., 1999) releasing the intracellular 
domain. The intracellular domain is then translocated to the nucleus to interact 
with members of CSL (CBF1/ RBPjk, Su (H), Lag-1) family of transcription 
factors replacing the corepressors. The CSL forms a complex with Skip, SMRT 
(Silencing Mediator of Retinoid and Thyroid receptors)/ N-coR (nuclear repressor 
co-repressor), CIR (CBF-1-interacting repressor) and histone deacetylases.  
Mastermind (MAML) protein is then recruited where it regulates the turnover of 
the intracellular by hyper-phosphorylation domain. The activated Notch 
transcription complex induces the transcription of target genes, including 
members of the Enhancer-of-split family of basic helix-loop-helix (bHLH) 
transcription factors that suppress cell fates (Mumm and Kopan, 2000; 
Schweisguth, 2004).  
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1.5 Notch in disease and cancer 
Abnormalities in expression of different Notch receptor components are 
implicated in progression of various diseases and cancers. Missense mutations or 
microdeletions in the EGF-repeats in Notch3 particularly in the cysteine 
residues are associated with the developmental vascular disorder known as 
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts 
and Leukoencephalopathy; (Joutel & Tournier-Lasserve, 1998). Another 
developmental disorder known as Alagille syndrome is caused by a mutation of a 
cystein residue in the 11th EGF-like repeat in Notch2. This syndrome which is 
characterised by clinical cardiac, ocular and facial defects is also caused by 
mutations in ligand Serrate 1 (McDaniell et al., 2006).  
 
The first evidence of a link of the mutations in Notch to cancer was found in T-
cell acute lymphoblastic leukaemia (T-ALL) patients. Chromosomal translocation 
was found in about 10% of the patients resulting in expression of Notch receptor 
where the extracellular domain was removed (Ellisen et al., 1991). In humans, it 
was found that 50% of (T-ALL) patients have activating mutations in the 
extracellular hetero-dimerisation domain and C-terminal PEST domain of 
Notch1. These mutations activated Notch1 signalling and showed an increase in 
transcriptional activity (Weng et al., 2004).  
 
1.6 Rationalising targeting Notch signalling 
Targeting the Notch signalling pathway has recently been reviewed and some 
unique features have been identified that could assist in rationalising the design 
of Notch inhibitors (Rizzo et al., 2008). Complete inhibition of the Notch pathway 
may not be required since Notch activation is dose-dependant. An intermittent 
inhibition of the Notch signal may be sufficient as the half-life of the active form 
is very short. Another essential feature that should be considered during the 
design of the treatment regimen is that Notch activity is expressed in different 
cells with different responses. There should be a means to modulate the Notch 
signalling without causing undesirable side effects. This may require a more 
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selective approach to targeting certain stages or steps in a more context-specific 
manner. Theoretically, the Notch pathway can be targeted at different levels, 
including ligand binding, fucosylation of Notch receptor, cleavage by ADAM 
proteases and γ-secretase, and protein-protein interactions of the Notch 
transcriptional complex.  
It is probably better to consider combination therapeutic regimens in targeting 
developmental pathways such as Notch. Such regimens are often developed by 
clinical trial and error when limited information of the mechanism of these 
pathways is available. A better understanding of the pathways and how they 
crosstalk with each other would help in designing these therapeutic regimens. 
The best combination regimen can be designed only after performing studies that 
can investigate and detect the type of cancers that are targeted by Notch 
inhibitors, the role of different components of the Notch pathway in cancer 
progression, and the pathways that crosstalk with Notch in certain cancers. 
However, this could be difficult as Notch is involved in an extensive cross talk 
network with other pathways. 
 
1.7 Inhibitors of γ-secretase 
The γ-secretase inhibitors found their ways into early stage clinical trials having 
the advantage of relatively easy oral administration and higher bioavailability 
(Shih & Wang, 2007). The main drawback of using γ-secretase inhibitors is the 
lack of specificity and selectivity. This is because they act on many substrates, 
including CD44, which is an important adhesion molecule for the extracellular 
matrix components and the intramembraneous cleavage product becomes a 
signal transduction molecule (Pelletier et al., 2006). E-cadherin is another 
substrate for γ-secretase that is a major cell-cell adhesion receptor important for 
different cellular behaviours. In order to disassemble the E-cadherin–catenin 
complex it is cleaved, releasing β-catenin, which is an essential modulator in the 
Wnt signaling pathway (Marambaud et al., 2002). γ-Secretase activates the 
release of the intracellular domain of ERBB4, a receptor tyrosine kinase (Vidal et 
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al., 2005). In addition, proteases participating in other cellular functions may be 
targeted by γ-secretase inhibitors. Another disadvantage of the γ-secretase 
inhibitors is their gastrointestinal toxicity; diarrhoea was observed in pre-clinical 
models caused by goblet cell metaplasia (Milano et al., 2004). This suggested the 
use of a combination therapy to reduce the gut toxicity, which includes adding 
glucocorticoids in addition to the antileukemic agents. 
 
1.8 Targeting the Negative Regulatory Region (NRR) 
The crystal structure of NRR of Notch2 revealed a possible mechanism by which 
the S2 cleavage is induced to activate Notch signalling (Gordon et al., 2007). It is 
proposed that after ligand binding the S2 becomes exposed through a significant 
conformational change that is caused by either a small allosteric change or a 
mechanical force. This dissociates the LNR from the HD (Heterodimerisation 
Domain) where the S2 site is buried in a hydrophobic groove (Gordon et al., 
2007). This could be a general mechanism in all Notch receptors, which share a 
high degree of sequence identity. The auto-inhibition conformation that protects 
the Notch receptor from ligand-independent activation suggests the possibility of 
targeting this region for developing potential therapeutic agents that modulate 
the Notch signalling. This is of particular interest especially in the treatment of 
T-ALL where mutations in the hydrophobic core of the HD are implicated in the 
development of T-ALL (Malecki et al., 2006). Antibodies have been developed to 
target the NRR of Notch3 (Li et al., 2008). Some antibodies were found to bind at 
one face of the NRR confirming the proposed model (Li et al., 2008)). Similarly, 
antibodies to target the NRR in order to antagonise Notch1 and Notch2 were 
generated to stabilise the off-conformation of NRR (Wu et al., 2010). In another 
study, two classes of highly potent antibodies were characterised in vitro (Aste-
Amézaga et al., 2010). The first group was ligand-competitive and targeted the 
ligand-binding site in the extracellular EGF-like repeats. The second group 
comprised the allosteric NRR-binding antibodies. 
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1.9 Development of peptidomimetics 
The assembly of a ternary complex composed of the intracellular domain, CSL 
and MAML is instrumental in switching on the transcription of Notch target 
genes. As described previously, the intraceullar domain interacts with CSL to 
form a long groove to allow for the binding of MAML. The role of MAML is 
crucial in stabilising the Notch complexes. MAML is an α-helical polypeptide 
that was shown to adopt an unexpected kinked structure in the ternary-DNA 
complex as revealed in the crystal structure (Nam et al., 2006) (PDB 2F8X). The 
crystal structure showed that neither the ankyrin domain nor CSL undergo 
major conformational change on complexation. This suggested that MAML could 
be considered as a recognition motif in the Notch transcriptional activation 
complex. In fact, Notch signalling has been shown to be antagonised by a 
dominant fragment of MAML (residues 13-74) (Maillard et al., 2004). This 
fragment, known as dnMAML, suggested that helix-mimetics such as 
hydrocarbon-stapled α-helical peptides might be useful.   
A number of peptides were designed that scan the contact surface with ankyrin 
and CSL (Moellering et al., 2009). Synthetic peptides that showed higher helical 
content bound with increased affinity to a binary RAMAnk-CSL complex. Such 
peptides were shown to suppress Notch1 gene expression in reporter gene 
assays, globally suppress Notch signalling in gene expression profiling 
experiments, reduce the proliferative capacity in T-ALL cell lines, and proved 
effective in vivo by inhibiting leukaemic progression (Moellering et al., 2009). 
These observations provide promising evidence of the possibility of a therapeutic 
agent acting as a direct transcriptional antagonist. However, the complexity of 
the system may lead to undesirable off-target activity.  
1.10 Druggability of protein-protein interfaces 
The possibility of small molecule drugs, so called new chemical entities (NCEs), 
modulating protein functions is referred to as the “druggability” of the target 
(Hajduk et al., 2005b). It has been used as a means for target identification and 
target validation. Several approaches have been devised to assess the 
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druggability of proteins. These methods rely on the application of geometry-
based or energy-based algorithms to 3D structures of proteins. Geometry-based 
methods were designed to predict concave pockets or calculate molecular surface 
complexity, whereas energy-based algorithms calculate the binding potentials or 
energies. However, most protein-protein interactions differ from protein-ligand 
interactions; it has been observed that protein-ligand interactions involve fewer 
and larger pockets whereas protein-protein interactions use numerous smaller 
pockets. Geometry-based methods were unable to predict small cavities on flat 
protein-protein interfaces. Energy-based methods on the other hand may be able 
to predict binding pockets, which are formed by adaptive or conformational 
changes on binding, using a dynamic model of the protein structure. 
Protein-protein interfaces have not evolved to bind to small molecules. Most are 
flat shallow surfaces that are devoid of deep pockets or cavities that can 
accommodate the binding of small molecules. Many protein-protein interactions 
appear to be achieved through the additive effect of numerous but weak 
interactions across the interface. It is quite difficult for a small molecule to 
mimic these widely-spaced interactions as it can participate only in a limited 
number of interactions. However, protein-protein interactions are important in 
many biological processes and in cases where the biology is understood have 
been implicated in disease progression; these targets have emerged as attractive 
drug targets despite their high chemical risk (Wells & Mcclendon, 2007). This 
has been encouraged by the discovery of hotspot residues that contribute a very 
large proportion of the binding energy at the interface. It was found that the 
energy of binding is not equally distributed across the interface and that the 
hotspot residues are usually enriched with tryptophan, tyrosine and arginine 
(Bogan & Thorn, 1998). Hotspot residues are investigated using alanine 
scanning mutagenesis. In this method, an amino acid is substituted with alanine 
and the change in the energetic contribution of the substituted residue to protein 
binding is recorded. Changes in the binding free energy of at least 2 Kcal/mol 
indicated a hot spot residue (Bogan & Thorn, 1998). Interestingly, these residues 
are usually surrounded by hydrophobic residues forming a water exclusion “O 
ring”. Protection from bulk solvent is necessary to strengthen the polar 
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interactions between complementary hot spot residues across the interface 
(Bogan & Thorn, 1998). Alanine scanning can be performed either by 
computational prediction or experimental site-directed mutagenesis which is 
rather tedious. The same hotspot region can bind to several targets suggesting a 
promiscuous binding behaviour of proteins involved in protein-protein 
interactions (DeLano et al., 2000). This adaptivity of proteins suggests that 
targeting these specific interactions by small molecules can possibly inhibit the 
interactions across the interface. A recent review by Wells and McClendon (Wells 
& Mcclendon, 2007) has described six successful stories of targeting protein-
protein interactions by discovering small molecules binding to hotspot residues. 
The discovery of nanomolar range inhibitors that bind to cytokine interleukin-2 
(IL-2) hotspot residues is an interesting example that has employed a fragment-
based approach. It was also shown in some cases that binding to a small 
molecule could trigger substantial conformational change revealing a potential 
binding cavity that was not seen either in the free protein or in complex. This 
could not be predicted computationally by virtual screening and requires 
experimental screening of molecules or inhibitors. Predicting the druggability of 
protein-protein interfaces still requires more knowledge and investigation of 
protein-small molecule recognition and its dependence on protein folds, the 
nature of the amino acids in the binding sites and the structural adaptivity of 
protein-protein interfaces to binding small molecules by inferring a certain 
degree of flexibility and mobility. 
 
Another hurdle that faces those who wish to modulate protein-protein systems is 
topological complexity of the interfaces; the two proteins that contribute to the 
interface both participate in protrusions and sub-pockets. One protein could 
contribute the most to the protrusions and becomes less likely to bind to small 
molecules. In addition, in some complexes the protein-protein interaction is 
regulated by phosphorylation. Developing a small molecule that mimics these 
charged species would result in a molecule that is too polar to be bio-available. 
Another important issue to consider is the functionality of the target: to consider 
whether the aim is to develop a molecule that inhibits the interaction or rather 
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restores the activity and function of the complex. In cases where the disease is 
caused by a loss of activity as a result of mutation, developing therapeutic agents 
to mimic and initiate a response becomes even more challenging.  
 
1.11 Advantages of targeting a protein-protein interface 
Protein-protein interfaces can provide an opportunity to develop selective 
inhibitors. Protein-protein interface inhibitors target hotspot residues, which are 
usually highly conserved compared to the other residues lying at the interface. 
This makes the proteins more resistant to spontaneous mutations at the binding 
site, probably based on the fact that a simultaneous complementary double 
mutation is uncommon and unfavourable in formation of a functional stable 
complex. A mutation or a change introduced in one amino acid in one protein at 
the protein-protein interface would adversely affect the affinity of one protein to 
the other.  
 
1.12 Examples for protein-protein inhibitors 
Peptidomimetics 
The first obvious approach to target a protein-protein interface is to mimic the 
natural binding ligand. However, peptidomimietics may not be the best choice, as 
they are susceptible to proteolysis, and thus less stable. Furthermore they have 
lower bioavailability due to their poor absorption, which is caused by their 
relatively higher molecular weight. They sometimes lack target specificity owing 
to their flexible conformations that enable them to interact with various 
receptors. However, they have been tested and developed as potential 
therapeutic agents that can block the function of some receptors. Different 
strategies aimed at overcoming these limitations have been developed, including 
modification of amino acids to stabilise the peptide against metabolism. This has 
been achieved by replacing the peptide bonds by structures that are not 
proteolysed, such as -CH2NH or by modifying the peptide backbone by 
introducing retro-inverse modifications using D- amino acids. In the case of 
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target proteases, peptide bonds have been replaced by structures that mimic or 
are isosteric with the enzyme transition state or intermediate, such as –CH(OH)-
NH-.  
Mimicking a secondary structure requires maintenance of both conformation and 
interaction. The α-helical structures can be mimicked either by using stapled 
peptides that enforce synthetic peptides to acquire a helical conformation, or by 
using a proteomimetic strategy that employs different scaffolds to reproduce 
critical contacts with the target protein.  
Stapled peptides are designed to enhance helical stability through incorporation 
of two α-methyl, α-alkenyl amino acids at positions separated by (i and  i+4) to 
form one helical turn followed by cyclisation to form a macrocyclic hydrocarbon 
crosslink (Kim & Verdine, 2009). A staple can also be formed at a position (i and 
i+7) to form two helical turns (Schafmeister et al., 2000). The activity of these 
stapled peptides is dependant on the stereochemistry of the cyclic hydrocarbon 
as helical content can influence cellular uptake. The helix stability also depends 
on the sequence of the peptide and the position of the crosslink. As it is difficult 
to predict the best conditions for helix stability, it is often necessary to synthesise 
and screen a small library in order to find the most active candidate. The other 
strategy is to design small molecules that mimic the residues at positions i, i+3 
or i+4, and i+7 of a ten-residue length α-helix.  
Numerous approaches have been employed to use scaffolds. For example, the 
template terphenyl has been substituted at three ortho-positions of the terphenyl 
scaffold by alkyl or aryl substituents to simulate an α-helix (Kim & Hamilton, 
2006). However, this resulted in a highly hydrophobic compound that has poor 
water solubility. The phenyl ring has been replaced by a heterocyclic ring to 
increase the hydrophilicity and this has improved solubility. The aqueous 
solubility was even improved when the terphenyl scaffold was replaced by the 
terphthalamide scaffold (Yin et al., 2005). An intramolecular hydrogen bond 
maintains a planar geometry keeping the central phenyl core. Adding an 
additional phenyl ring in the core allows for a higher degree of specificity as it 
mimics a four-residue α-helix. 
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Peptidomimetics tend to be most succesful where the protein-protein interface 
involves continuous binding peptides that contribute significantly to the overall 
affinity between the protein units (Arkin & Wells, 2004).  
 
                              A                                  B                                C 
                                                                         
Figure 1.3 Examples of peptidomimetics. A) Terphenyl derivatives B)Terphthalamide C) Stapled 
peptides 
 
1.13 Fragment-based approach 
The “Lipinski rule of 5” has been devised to describe orally active drugs (Lipinski 
et al., 2001). Although many drugs that reached the clinic have deviated from 
one or two rules (Wenlock et al., 2003), they are still useful as a guideline for 
identifying drug-like molecules. However, these rules need some qualification for 
assessing lead-like molecules during drug development. Lead compounds usually 
have lower molecular weights, lower lipophilicity and fewer hydrogen-bond 
acceptors. This is expected, as starting with compounds of drug-like properties 
would lead to compounds of poorer physical properties during optimisation. This 
suggested that starting with smaller molecules would result in drug candidates 
with more favourable properties. The “Lipinski rule of 5” was then replaced by a 
“rule of three” (Congreve et al., 2003) that helped in establishing screening 
libraries known as fragments and referred to also as needles (Boehm et al., 2000) 
seeds (Liebeschuetz et al., 2002) and shapes (Fejzo et al., 1999). 
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Table 1.1 The different parameters of Lipinski rule of 5 and rule of three  
  Lipinski Rule of 5 Rule of three 
Molecular Wgt 
H-bond donors 
H-bond acceptors 
Rotatable bonds 
  LogP 
<500 
≤ 5 
≤ 10 
≤ 5 
≤ 5 
<300 
≤ 3 
≤ 3 
≤ 3 
≤ 3 
 
The advantages of using a fragment-based approach are many. First, smaller 
screening libraries can cover an acceptably diverse chemical space. The 
estimated 1063 of small drug-like compounds (Bohacek et al., 1996) makes it 
impossible to assemble HTS (High-throughput screening) libraries that cover 
more than a very tiny portion of the chemical space.  On the other hand, smaller 
fragment libraries can explore the same chemical space as a larger library of 
drug–sized molecules. This not only reduces the screening time and synthesis, 
but it is advantageous in data analysis and management. Second, the successful 
hits identified are likely to have a higher ligand efficiency compared to those 
obtained by other methods. Ligand efficiency is a measure of the potency of a 
compound, measured by calculating the average free energy of binding per heavy 
atom (Hopkins et al., 2003). It is a useful means to prioritise initial hits and 
assess the compounds throughout the optimisation process as it eliminates any 
bias introduced by an increase in molecular weight. Small molecules such as 
fragments form fewer but often better binding interactions. Starting with small 
fragments of high ligand efficiency would lead to compounds of better 
pharmacokinetics. This could also be due to the fact that fragments libraries can 
be selected to avoid unfavourable functional groups. Third, fragment libraries 
are expected to have higher hit rates than conventional screening libraries of 
more complex and larger compounds, although this will be dependant on the 
sensitivity of the screening method used to detect the weakly-binding fragments. 
Simple fragments could have high complementarity to protein targets. The 
identified hits can then be optimised by adding chemical groups, in order to 
increase complementarity between protein and ligand. 
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Fragments can be developed into lead compounds by fragment evolution or 
growing, fragment linking, fragment optimisation and fragment self-assembly. 
Fragment evolution can be achieved by adding new functionalities to the 
fragment in order to introduce new interactions to adjacent regions in the 
binding site. Fragment linking seems to be an attractive approach when two 
fragments bind in proximal positions in the active site enabling them to be 
linked together. In fragment self-assembly, the protein acts a template for the 
reactive fragments that link together to form an active compound. On the other 
hand, fragment optimisation involves a modification in only certain 
functionalities to improve properties or solve problems. 
These approaches may seem daunting when attempting to transform a 
millimolar fragment hit to a nanomolar lead drug. However, it can be facilitated 
by strategic structure-based drug design. Structural information about the 
binding modes of fragments can be obtained by NMR or X-ray crystallography. In 
fact, it is thought that structure-based drug design aided in tripling the success 
of producing potent inhibitors (Hadjuk & Greer, 2007). 
 
1.14 Properties of protein-protein inhibitors 
Analyses of the physical and chemical properties of protein-protein inhibitors 
show they have significantly higher molecular weights than those that target 
conventional receptor binding or enzyme active sites (Higueruelo et al., 2009; 
Sperandio et al., 2010). Larger molecules tend to be necessary to duplicate even a 
small subset of the widely spaced interactions across the interface. They are also 
observed to be more rigid and have restricted orientations; they tend to have 
more rings and less rotatable bonds. This rigidity can be advantageous in 
reducing energetic penalties associated with the loss of entropy. In addition, rigid 
molecules can create new sub-pockets in the target protein by displacing flexible 
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protein regions. They are also likely to be more lipophilic with fewer hydrogen-
bond acceptors and donors.  
Early attempts to develop protein-protein inhibitors were focused on mimicking 
protein ligands including replacing chemical moieties and side chains with 
similar functional groups. However, some inhibitors that displayed non-exact 
matches were effective as long as they form interactions in the binding site. 
 
1.15 Targeting protein-protein interfaces using fragment-based approaches 
The compounds used in HTS screening are mainly derived from well-known 
chemical phenotypes that have been characterised from extensive research on 
traditional drug targets such as G-protein-coupled receptors and enzyme targets. 
These compounds may not be the most appropriate for targeting protein-protein 
interfaces. The observations recorded in the previous section suggest that 
enriching the standard libraries with compounds that comply with the properties 
of successful protein-protein modulators may increase the hit rate, enhance 
potency and improve specificity for protein-protein interactions. Indeed 
inhibitors of protein-protein interfaces may require new scaffolds or new classes 
of compounds. Fragment screening could then be the preferred approach for 
exploring a larger chemical space with higher ligand efficiency.  
 
1.16 Fragment screening methods 
Screening weakly binding fragments can be carried out by either biochemical 
assays or biophysical methods. 
i) Biochemical method 
Biochemical assays are often referred to as high concentration screening (HCS) 
as they are performed at high fragment concentrations that can often reach 
millimolar range. These functional assays can be configured in two different 
ways. Enzymatic activity can be monitored by the presence or absence of 
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substrate or by accumulation of product or by-product. Alternatively, fluorescent-
based molecules can be used to trace the displacement of a known ligand. In the 
presence of a correct compound template, the allosteric site binders can be 
identified. HCS offers the advantages of a fast, quantitative, and a highly 
scalable method once the essay setup is established. However, false positives can 
occur by compound aggregation at high concentrations or lack of effective 
solubility. Cell toxicity caused by high concentration compounds in cell-assays 
makes this assay unsuitable for some targets. 
ii) Biophysical methods 
Biophysical methods are the more popular approach to screening fragment 
libraries; they include direct biophysical assays or direct structure-based 
screening. 
a) X-ray crystallography screening: 
 Automation of data collection, analysis and interpretation has made it possible 
to use X-ray crystallography as a screening method (Mooij et al., 2006). Cocktails 
of fragments dissolved in an organic solvent are used to soak crystals. The 
cocktail size can be up to eight compounds depending on the ability of the 
crystals to tolerate higher concentrations of the organic solvent. False positives 
can be greatly reduced as the bound compound can be visualised and decisions 
made for improving the binding in a structure-based manner. However, this 
technique is time and resource consuming, requiring production of significant 
amounts of protein, usually in milligram quantities, in order to grow crystals of 
reasonable quality. False negatives are quite frequent for either kinetic or 
crystallographic reasons or when the fragments are poorly soluble in the 
crystallisation medium.       
b) NMR screening: 
The identification of small molecules binding to a protein and linking them 
together using NMR-based method was first carried out in Abbott laboratories 
(Shuker et al., 1996). This approach, which has been known as “SAR by NMR”, 
21 
 
can detect weakly binding molecules in the millimolar range (Shuker et al., 
1996). Since then, it has been applied for screening fragment libraries. In fact, it 
has been used as an experimental druggability assay (Hajduk et al., 2005a).  
False positives or negatives are difficult to identify in this screen. Some 
structural information can be obtained and unlike X-ray crystallography binding 
affinities can be measured. NMR screening can be configured in two ways. A 
protein-based NMR assay makes use of sensitive 1H-15N or 1H-13C correlation 
NMR for detecting small molecules binding. Local chemical shift perturbations 
can indicate a ligand binding event. However, screening is restricted to proteins 
amenable to isotopic labelling which is time consuming and not suitable for all 
targets as it requires a large amount of protein which makes it difficult to screen 
proteins with limited solubility or larger proteins (larger than 50KD). The 
alternative is to carry out ligand-detected NMR assays which do not need any 
protein labelling allowing for a rapid assay setup. Water ligand optimised 
gradient spectroscopy (WaterLOGSY) technique depends on the fast ligand 
exchange between the bound and unbound forms (Dalvit et al., 2000). This 
method exploits water magnetisation and bound ligands show positive signals. It 
can detect affinity values between 10µM and 10mM. Unlabelled protein without 
any size limitations can be used in this case.  
c) Fluorescence-based thermal shift assay: 
This rapid screening method exploits the stabilisation of the protein in the 
presence of the compound by monitoring protein unfolding in the presence of a 
fluorescent dye. This method is discussed in detail in Chapter 3. 
d) Surface plasmon resonance 
The enhanced sensitivity of surface plasmon resonance methods has allowed the 
study of weakly binding compounds such as fragments. Once the setup is 
optimised, it can be used as a high throughput method. This method is described 
in more details in Chapter 5. 
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e) Isothermal calorimetric titration 
This method is not considered a high-throughput method for screening fragment 
libraries as it requires large quantities of proteins. In addition, it sometimes can 
not detect very weakly binding fragments. However, it is a powerful method for 
deriving important thermodynamic parameters such as enthalpy and entropy of 
binding of ligands. A recent review by John Ladbury has emphasised the 
importance of measuring these parameters during the drug discovery and 
optimisation process (Ladbury et al., 2010). Such data is complementary for hit 
prioritisation and hit-to-lead optimisation. Future development of the 
instrumentation may transform this technique to a popular method in fragment 
screening. 
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1.17 Objectives 
The main objective of this study was to probe the druggability of the ankyrin 
domain of human Notch1 receptor. The architecture of the ankyrin domain as a 
repeat protein facilitates its role as a scaffold for binding other proteins. It is 
involved in many protein-protein interactions but so far there have been no 
reports of any small molecules that can bind to the ankyrin domain. Finding 
small molecules would be advantageous in developing compounds that could 
interfere with the protein-protein interactions involved in the Notch 
transcriptional complex with CSL and MAML. The ankyrin domain is 
instrumental in Notch signalling and targeting it with small molecules would be 
a promising approach to replacing existing therapeutic agents with a lead-like or 
drug-like chemical entity. 
I have embarked on investigating the druggability of the ankyrin domain using a 
fragment-based approach. The following chart describes the route I followed. 
 
 
 
 
 
                                                                                                                                                             
                                                                                                                                                          
                                                                                                                                                         
                                                                                                                                                          
 
In Chapter 3 and Chapter 5, I test the druggability of the ankyrin domain by 
screening a commercial fragment library and measuring the hit rate in order to 
Ankyrin domain as a 
target 
Fragment Library screening by 
fluorescent-based thermal shift assay 
Fragment characterisation by Surface 
Plasmon Resonance (SPR)
Validation of binding sites using X-ray 
crystallography 
Computational optimisation using GOLD for 
docking and SPROUT for de novo design 
Chapter 3 
Chapter 5 
Chapter 4 
Chapter 6 
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investigate the likelihood of binding small molecules. The objective here is to 
identify the most favourable scaffolds or chemical moieties that could bind to the 
ankyrin domain and the functionalities that could destabilise it. Measuring the 
affinities of fragments and optimised fragments should assist in developing 
molecules in a SAR manner. 
The objectives of the research described in chapters 4 and 6 are to identify 
binding sites of the fragment hits and to detect any small cavities on the surface 
that could accommodate binding to small fragments. A structure-based approach 
with the assistance of computational tools such as docking and de novo drug 
design software is used to develop and optimise the fragments identified by these 
methods. The research indicates that a fragment-based approach may provide a 
route to identifying leads targeting such “undruggable” protein-protein 
interaction sites. 
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Chapter 2 
Preparation and Analysis of the Ankyrin 
domain 
Many biophysical experiments require highly pure, stable, soluble and 
homogeneous protein. The degree of purity varies according to the technique and 
its sensitivity. In NMR studies, two-step purifications are often sufficient to yield 
protein samples with the required purity level for initial spectra. On the other 
hand, crystallography needs a higher degree of purity in order to allow 
reproducible crystal growth in crystallisation trials. An additional purification 
step often ensures the removal of any impurities that could interfere with crystal 
packing. In an iterative structure-based drug discovery programme, high protein 
expression enables the use of different methods for screening compounds, hit 
identification, hit characterisation and crystallisation to obtain protein-ligand 
structures. The first step is to establish a systematic scheme for protein 
expression and purification in a reproducible manner. 
In this chapter I describe the expression and purification of the ankyrin domain 
for structural analysis and its initial biophysical characterisation using circular 
dichroism. I also describe an assessment of the potential binding sites in the 
ankyrin domain by examining its interactions in the three-dimensional structure 
of the Notch transcription complex. This was performed using the relational 
database PICCOLO and by analysing mutational studies data.  
2.1 Protein expression and purification 
    2.1.1 Chemicals 
The chemicals used were from either Sigma-Aldrich (St. Louise, MO), or Melford 
Laboratories (Ipswich, UK), unless stated otherwise.    
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2.1.2 Protein expression: 
 The construct pET41a (+) encoding the human Notch1 ankyrin domain 
(Ehebauer et al., 2005) was transformed into Rosetta (DE3) Escherichia coli. 
Cells were grown in 1 L 2xYT medium containing 34 μg/ml chloramphenicol and 
25 μg/ml kanamycin in a shaking incubator at 37ºC. When the OD600 reached 0.6, 
they were induced with 1mM IPTG for 3 hours. 
The cells were harvested by centrifuging at 5,000 ×g for 20 minutes. The pellet 
was then resuspended in 25 ml of 20% sucrose; 50 mM Tris-HCl (pH 8.0); 150 
mM NaCl containing one protease inhibitor tablet (Complete EDTA free-Roche) 
and 1mg/ml of lysozyme grade VI chloride. 
 2.1.3 Protein purification                                                     
The resuspended pellets were sonicated  (Sonicator XL2020, Misonix) on ice 
using 30 second pulses for a 2 minute period, centrifuged at 17,000 × g for 30 
minutes. The supernatant was loaded onto Ni-NTA agarose (QIAGEN) column 
with a 5 ml bed volume.  The column was washed twice with 10 ml of 50 mM 
Tris-HCL (pH 8.0); 50 mM NaCl; 50 mM imidazole and then eluted twice with 10 
ml with 50 mM Tris-HCl (pH 8.0); 300 mM; 150 mM imidazole. The first eluent 
fraction was then loaded onto a HiTrap Q-HP anion–exchange column 
(Phenomenex) pre-equilibrated with buffer A: 50 mM Tris (pH 8.0); 50 mM NaCl. 
Protein was eluted using a gradient of 0-100% of buffer B: 50 mM Tris-HCl (pH 
8.0); 1 M NaCl over 20 column volumes. Collected fractions were loaded onto a 
Superdex 200 HR 10/30 size exclusion column (Phenomenex) and eluted 
using 50 mM Tris-HCL (pH 8.0) and 50 mM NaCl. 
 
 
2.1.4  Results and discussion 
The ankyrin domain was expressed as a C-terminal-His-tagged protein. The first 
purification step used affinity chromatography employing a Ni-NTA affinity 
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column. Analysis of the eluate fractions by SDS-PAGE showed some protein 
contaminants that were removed by further purification steps. Ion exchange 
chromatography was used as a second purification step. After visualising the 
protein on SDS-PAGE, the fractions that contained the protein were pooled 
together for a final polishing purification step by size exclusion chromatography 
(Figure 2.1). 
 
                          
                         
 
 
Figure 2.1 Purification of the ankyrin domain by Ni-NTA anion exchange chromatography (AEC) 
and size exclusion chromatography (SEC). A) SDS-PAGE showing Ni-NTA purification. 
(M=Marker,FT= flowthrough ,W(1-2)=wash 1,E(1-2)= elution)  B) SDS-PAGE showing AEC and 
SEC fractions C) anion exchange chromatpgraphy D) size exclusion chromatography  
 
 
The single peak indicated a highly pure protein that could be used for further 
experiments. 
 
 This protocol was adapted from Ehebauer et al. and assessing its reproducibility 
was essential before proceeding in any future experiments. Batch-to-batch 
variations can become problematic in iterative processes. It was possible to 
purify the protein in one day which makes it very convenient for repetitive 
experiments. The ankyrin domain was expressed giving a reasonable yield of 
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about 5 mg/L of media. As shown in Chapter 3, about 20 mgs are required for 
screening a fragment library. More protein was required to produce crystals to 
optimise soaking conditions and for co-crystallisation attempts with fragments 
and ligands as described in Chapter 4. The kinetic characterisation using 
Surface Plasmon Resonance described in Chapter 5 utilised only small quantities 
of protein. 
 
 
2.2 Circular dichroism spectroscopy 
 
2.2.1 Material and Methods 
 
The far-UV circular dichroism spectrum of the ankyrin domain was recorded 
using an Aviv 215 circular dichroism spectrometer (Aviv Instruments Inc.). The 
spectrum was recorded at 20°C in a clean 0.1 cm quartz cell, using an average 
time of 0.5 seconds and a step size of 0.5 nm. The spectra of 15 scans were 
averaged and subtracted from the baseline of the buffer containing 50 mM Tris 
pH8 and 50 mM NaCl. 
 
The denaturation of the ankyrin domain was recorded at 222nm due to its high 
helical content. The temperature range set between 20°C and 90°C and the 
temperature range was fixed at 0.1°C. The equilibration time at each 
temperature was adjusted to 0.5 min with heating rate 1°C per minute. 
Ellipticity (y) is plotted against temperature (x) to examine the unfolding curves. 
 
 
 
2.2.2 Results and discussion 
 
Circular dichroism (CD) is a spectroscopic technique used to investigate the 
folding and unfolding of proteins, to gain clues about the effects of mutations and 
ligand binding on protein structure, and to estimate the secondary and tertiary 
structures of proteins. This phenomenon, which is exhibited by optically active 
molecules, relies on the differential absorption of left and right circularly 
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polarised light. For proteins, the secondary structure is studied in the far-UV 
region at wavelengths (180-250 nm) where the peptide bond absorbs. The 
characteristic CD-spectra have minima at 208 and 222nm when there is alpha-
helix, at 218nm for β-sheet and at 198nm for random coil. The near-UV region 
(250-350 nm), where aromatic amino acids absorb, provides information on the 
tertiary structure.  
 
The CD spectrum of the ankyrin domain was recorded in order to investigate its 
structural stability. The CD spectrum revealed two minima at 208 and 222 nm, 
indicating a predominantly α-helical protein (Figure 2.2). This confirmed the 
quality of the protein and its folded nature. Further experiments could then be 
conducted on the ankyrin domain for drug discovery purposes. 
 
The unfolding temperature of a protein can be measured by recording the CD 
spectrum as a function of temperature at a fixed wavelength. This assists in 
determining the presence of any unfolding intermediates, and can be used to 
identify changes in unfolding caused by variations in salt concentrations or pH. 
Two-state unfolding is indicated by a sigmoidal curve, from which the unfolding 
temperature Tm is estimated from the midpoint. The ankyrin domain unfolded in 
a two-state manner despite its modular architecture (Figure 2.3). The Tm was 
estimated to be around 45° C and its unfolding behaviour indicated that it would 
be possible to employ a fluorescent-based thermal shift assay as a screening 
method. In this method, the protein is required to reproducibly unfold in a two-
state manner to measure the difference of Tm in the absence and presence of 
fragments or compounds. 
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Figure 2.2 Far-UV CD spectrum of the ankyrin domain showing two minima at 208 nm and 220 
nm. 
                     
Figure 2.3 Denaturation curve showing the ellipticity as a function of temperature to determine 
the unfolding temperature at the midpoint of the curve. 
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The interactions between the ankyrin domain and MAML predicted by 
PICCOLO were predominantly ionic interactions (Figure 2.5). This included 
charged interactions between acidic residues at loops between repeats three and 
four of the ankyrin domain and turns three and four of MAML. As shown by the 
crystal structure, the helical MAML polypeptide bends at Pro46 (Nam et al., 
2006). The ankyrin domain interacts with the first region of MAML before it 
bends. A second subset of hydrophobic interactions are observed between turns 
seven to nine of MAML and repeats six and seven of the ankyrin domain (Nam et 
al., 2006). The residues of the ankyrin domain involved in the interaction with 
MAML are mainly at the interface periphery as predicted by PICCOLO and are 
mostly charged residues. 
Charge reversal mutations of selected residues of MAML were carried out to 
investigate their importance in the formation of the transcription complex (Del 
Bianco et al., 2007). Single mutation of R25 to glutamate prevented the formation 
of the complex whereas single mutations of residues R22, R26, R31, E38, R53 
and T56 did not have any inhibitory effect. Double mutation of R22 and R25 had 
a dominant negative effect.  
 
 
 
Ankyrin residues Ankyrin domain 
interface solvent 
accessibility 
MAML residues Type of interaction 
Tyr2075 
His2107 
Asp1973 
Gly2073 
Asp1973 
Asp2109 
Glu2009 
Glu2009 
Asp2109 
His2108 
Ala2007 
Met2106 
Met2106 
 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
Interface periphery 
 
Arg40 
Arg40 
Arg22 
Arg40 
Arg40 
Arg26 
Arg22 
Arg25 
Arg40 
Glu47 
Glu47 
Val44 
Leu29 
 
Pi-cation 
Pi-cation 
hydrogen-bond 
hydrogen-bond 
hydrogen-bond 
ionic 
ionic 
ionic 
ionic 
ionic 
hydrophobic 
hydrophobic 
hydrophobic 
 
 
Table 2.1 A list of the properties of the interactions between the ankyrin domain and MAML
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in ionic and hydrogen-bond interactions. The basic residues are more abundant than 
acidic residues. 
 
Similarly, mutational studies were conducted to investigate the importance and 
significance of the interacting residues on stabilising the transcription complex 
(Deepti Gupta, unpublished; Del Bianco et al., 2007). A limited alanine scan of 
was carried out of the ankyrin domain residues at the ankyrin-CSL interface and 
ankyrin-MAML interface. This included residues; R2005A, W2035A, E2072A, 
and E2076A at the ankyrin-CSL interface and residues D1973A, E2009A, 
N2040A and D2109A at the ankyrin-MAML. None of these mutations affected 
the formation of the ternary complex in size-exclusion chromatography. 
However, charge reversal mutations of two particular residues prevented the 
formation of the ternary complex. Single site mutations of D1973R and E2072R 
disrupted the formation of the complex in chromatographic assays. These 
mutations also inhibit the induction of transcription in cell-based reporter 
assays. This suggested that the electrostatic complementarity is essential for the 
assembly of the transcription complex. In addition, multisite substitution of 
residues (E2072K/ D2095V; R1963E/ R2005E/ E2072K; V2039D/ E2072K/ 
D2095V and R1963E/ R2005E/ E2072K/ D2095V) appeared to have a more 
pronounced effect in transcription inhibition suggesting an additive effect 
(Deepti Gupta, unpublished). 
 
There is no conformational rearrangement observed in either the ankyrin 
domain or CSL structures after complex formation. Differences in the backbone 
chain of CSL when compared with the Caenorhabditis elegans CSL:DNA 
complex (Kovall & Hendrickson, 2004) alone can be attributed to crystal packing.  
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The Notch transcription complex appears to be stabilised by numerous additive 
electrostatic interactions. The lack of evident hotspot residues makes it difficult 
to modulate the protein-protein interactions. Inhibiting several interactions 
simultaneously may be required in order to inhibit complex formation. 
Identifying small molecules such as fragments that could interfere with these 
numerous interactions seems to be a sensible approach.  
 
The ankyrin residues interacting with MAML lie at the interface periphery of 
the ankyrin interface which is solvent accessible. This can suggest that polar 
molecules are more likely to bind to this region. The interface periphery of 
protein-protein interfaces is usually rich in arginines and histidines (Richard 
Bickerton, unpublished). However, only two histidine residues were detected at 
the interface periphery of the ankyrin domain with MAML. Acidic residues are 
more abundant forming ionic and hydrogen bond interactions.  
 
On the other hand, the interface of the ankyrin domain with CSL constitutes 
mainly of residues at the interface core. This region is usually enriched with 
tryptophan, tyrosine and methionine residues (Richard Bickerton, unpublished). 
However, none of those residues were observed at the interface core of the 
ankyrin domain. Instead, arginine residues were favoured engaging in hydrogen 
bonds and ionic interactions. 
 
The nature of the interactions of the ankyrin residues interacting with CSL and 
MAML is broad and diverse. Finding small molecules that could interfere with 
these interactions may require screening a more diverse library. Fragment 
libraries can provide a larger chemical space for targeting the ankyrin domain 
interface. 
 
 
 
Chapter 3  
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Fragment Library Screening 
3.1 Introduction to Fragment Screening 
3.1.1 Fragment library design 
The design of a screening library is of paramount importance, as it will influence 
the direction of drug discovery and development of the initial hits. The factors 
that should be considered when establishing a fragment library (Leach et al., 
2006) depend on the screening technique and on screening concentrations, the 
higher the concentration the smaller the library. The novelty of the target and 
knowledge of natural or known ligands also determine how focused the library 
should be.  
Physical properties of the fragments are key to setting up a library. The 
solubilities of the fragments are important, although difficult to predict and need 
to be measured experimentally. The numbers of hydrogen-bond donors and 
acceptors, together with the cLogP value can give an indication of the solubility. 
Since the fragments are usually screened at higher concentrations (up to 10 mM) 
in aqueous buffers, the fragments should have considerable water solubility. The 
solubility of fragments can be improved by using organic solvents as co-solvents. 
DMSO is usually used at concentrations of 1% to 10%, depending on the 
screening technique, in order to minimise aggregation and false positive hits. 
The purity of the fragments is critical in screening, as impurities can interfere by 
encouraging aggregation or interacting with the target irreversibly, leading to 
false positive hits. However, this will depend on the sensitivity of the screening 
technique as well. 
The chemical properties of the fragments define the diversity of the library. It is 
preferable that the fragment library contains similar molecules to confirm 
positive hits as well as to define SAR even with small molecules. The fragments 
should be devoid of any toxicophore or reactive groups; several filters allow 
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excluding such molecules (Verheij et al., 2006; Roche et al., 2002). The feasibility 
of synthesis and chemical elaboration should be considered as well: the molecules 
should contain a “chemical handle”, which allows for further elaboration through 
growing or linking. Several functional groups are used as chemical handles, 
including carboxylic acid and nitrile groups. Although this provides an attractive 
way to develop the fragment from hit to lead, it limits the search for novel hits. 
There has always been a search for new scaffolds representing a much broader 
chemical space. Interestingly, very few new synthetic compounds are published 
every year even though it has been demonstrated that around 3000 synthetically 
tractable new compounds need to be explored (Pitt et al., 2009). Many of these 
will be challenging to synthesise, or incompatible with the biological systems as 
the authors suggested (Pitt et al., 2009). 
The physical and chemical requirements for constructing a representative 
fragment library led to the suggestion of a “rule of three” (Congreve et al., 2003). 
This rule is derived by analogy with the “Lipinski rule of five” and indicates that 
molecular weight should preferably be ≤ 300, the number of rotatable bonds ≤ 3, 
the number of hydrogen bond acceptors and donors both ≤ 3, cLogP ≤ 3 and the 
polar surface area ≤ 60 Å2. 
The fragment library used in this study is a commercial library supplied from 
Maybridge and complies with the rule of three (Congreve et al., 2003). . This 
library that I used included 100 extra compounds prepared in the Chemistry 
Department, University of Cambridge in the laboratory of Professor Chris Abell, 
in addition to the Maybridge set. The library is maintained in Chemistry for 
screening a range of targets; it is not target-tailored but it is reasonably diverse. 
             
3.1.2 Screening Techniques 
The screening methods should be sensitive enough to identify weakly binding 
fragments. Ideally, biological in vivo assays would be the best way for screening 
and identifying potential hits. However, these molecules are weak binders and 
interact in low µM or mM concentration ranges, which are usually not detected 
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in assays. Biophysical in vitro screens are normally carried out instead. They 
have the advantage that they can detect the fragments that bind and interact 
directly with the target without interference from other cellular proteins that are 
often found in biological assays. The biophysical techniques vary in their 
sensitiveness, their hit rate, their advantages and disadvantages, and their 
requirements for both target and fragment library. The choice of screening 
method depends primarily on the protein target, i.e. whether it can meet the 
requirements of the technique, its availability and the ease of interpreting the 
screening data.  
3.2 Fluorescent-based thermal shift assay screening 
3.2.1 Background of fluorescent- based thermal shift assays 
The fluorescent-based thermal shift assay can be considered a high-throughput 
screening technique in drug discovery. It has emerged as a rapid technique for 
hit identification, based on energetic coupling events between the ligand and 
protein unfolding. These energy transformation processes cause ligand-induced 
changes in protein unfolding curves (Pantoliano et al., 2001). The unfolding is 
thermally induced and measured in the presence and absence of ligands. Protein 
unfolding can be monitored by environmentally sensitive dyes, which have 
different quantum yields depending on the dielectric constant value of the 
solvent or surrounding environment (Pantoliano et al., 2001). As the protein 
unfolds, it exposes hydrophobic regions that resemble a low dielectric constant 
solvent resulting in an increased fluorescence. In this study, SYPRO® orange 
(Invitrogen) was used as the fluorescent dye. 
 
3.2.2 Advantages of fluorescent-based thermal shift assays 
This method has become a popular method in the past few years as a 
preliminary screening method. It is regarded as a high-throughput screening 
technique owing to its rapidness, cheapness and simplicity. It is suitable for 
screening protein targets of unknown functions or unknown ligands. There is no 
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special treatment or labelling required for either the protein or the compounds.  
Minimal amounts of protein are required for screening large libraries; 10 mgs of 
protein can be used to screen about a 1200 compound library. Highly purified 
protein samples are not necessary, 75% pure samples can be used for screening 
as indicated by Pontoliano et al. (2001). 
3.2.3 Limitations of fluorescent-based thermal assay screening 
This assay is a simple preliminary screening method that gives a quick yes/no 
answer. However, as for any screening method, several limitations should be 
considered when screening and analysing data. Compounds can bind to both the 
folded and unfolded state of the protein, decreasing the ∆Tm   value and causing a 
false negative. In addition, highly fluorescent compounds produce a high 
fluorescent background, giving a lower ∆Tm value and leading to false negative 
hits as well.  The method is limited to proteins that unfold in a two-state 
manner, where the Tm value can be easily determined. Binding affinities can be 
difficult to calculate, as the binding enthalpy can be overestimated. A technical 
limitation can rise from the instrumentation itself, because of the optical edge 
effects of using a CCD (closed-circuit device) camera for fluorescence detection. 
This leads to variation of excitation light and fluorescence intensities between 
different samples.  
In this chapter, I describe the optimisation of the screening conditions by buffer 
screening and the screening of a small fragment library against the ankyrin 
domain. 
 
 
 
 
3.2.4 Buffer Screening 
3.2.4.1 Materials and methods 
41 
 
The ankyrin domain was expressed as described previously (See Chapter 2). 
Stock protein solution was frozen at a concentration of about 315 µM (10 mg/ml). 
It was diluted with original buffer, which constituted of 50 mM Tris pH 8, 50 mM 
NaCl to reach a concentration of 10 µM (about 1.65 mg/ml). The buffer screening 
was carried out in thin-walled plates (Bio-Rad) and sealed with caps (Bio-Rad). 
The solutions were added to form a final volume of 100 ul as shown in table 3.1. 
The buffers were screened at 10 mM and some were screened at 20 mM. Water 
was added instead of the buffer in the control samples. The plates were then 
heated in an iCycler iQ Real Time PCR Detection System (Bio-Rad) from 25 °C to 
60 °C with 0.5 °C increments. Fluorescence was detected by a CCD camera. 
SYPRO® orange dye has fluorescence excitation and emission wavelengths 490 
and 525 nm, respectively.  The buffers used for screening are shown in table 3.2. 
 
 
        Table 3.1   Reagents used in buffer screening 
                      Reagent                      Concentration 
                       
                           Protein                   8 ul   (final concentration 10 uM) 
                       SYPRO orange          25 ul (1:250) 
                            DTT                      5 ul   (final concentration 5 mM) 
                           Buffer                    10 ul or 20 ul  (final concentration 10 mM or 20 mM) 
                            NaCl                      50 mM and at 400 mM 
       
                   
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Buffer list used for screening, the pH values and the concentration used for screening. 
 
 
                Number                   Buffer                    pH                concentration     
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                        1                           CHES                    8.5                   10 mM, 20 mM 
                        2                  Sodium Phosphate        7                      10 mM, 20 mM 
                        3                           Bicine                    9                      10 mM, 20 mM 
                        4                  Sodium Phosphate         5                     10 mM, 20 mM 
                        5                     Sodium Acetate           4.6                  10 mM, 20 mM 
                        6                            Glycine                10                     10 mM, 20 mM 
                        7                            Borate                   8.5                   10 mM, 20 mM  
                        8                            Tris                       8                      10 mM 
                        9                        bis Tris                     6.7                    10 mM 
                      10                        PIPES                      6                       10 mM 
                      11                      Sodium Citrate          5.6                    10 mM 
                      12                             MES                     6.5                   10 mM 
                      13                        Imidazole                  8                      10 mM  
                      14                           CAPS                   10.5                    10 mM   
                      15              Sodium cacodylate             6.5                   10 mM             
 
 
 
 3.2.4.2   Results 
 
 
The ankyrin domain was screened in 15 buffers at pH values varying from pH 
4.6 to pH 10.5 at usually at 10 mM but sometimes at 20 mM buffer 
concentration. None of the buffers screened at 50 mM NaCl salt concentration 
showed any stabilisation of the protein (Figure 3.1). The Ankyrin domain did not 
unfold in a two-state manner as demonstrated before (Zweifel & Barrick, 2001), 
but showed some melting profiles indicating complex unfolding patterns and 
instability. When the concentration of the salt was increased to 400 mM, one 
buffer only, buffer CHES at pH 8.5 was able to stabilise the ankyrin domain 
(Figure 3.2). Then the protein unfolded in a two-state transition and showed 
reproducible unfolding curves. The average Tm value was 43 °C. That is 
approximately 3 °C higher than previously reported in Drosophila (Zweifel & 
Barrick, 2001), and this could be attributed to the higher salt concentration. 
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Figure 3.1 The derivative unfolding curves of the protein in different buffers at low salt 
concentration. Many peaks appeared indicating some instability followed by what seems to be 
aggregation. 
 
 
 
 
 
Figure 3.2 Derivatives of the melting curves for the buffer screens in high salt concentration. The 
only buffer that showed a reproducible two-state unfolding transition was CHES pH 8.5 as shown 
which appears as a chevron.  
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3.2.4.3 Discussion  
Buffer screening is a useful way to optimise buffer conditions for various 
purposes.  Optimising biophysical properties of proteins, such as solubility, 
homogeneity and stability is important for protein crystallisation. Thermofluor-
based buffer optimisation has been widely used to improve crystallisation-hit 
rates (Ericsson et al., 2006). 
The ankyrin domain is a repeat protein that comprises seven ankyrin repeats. 
The characteristic architecture of the ankyrin repeats would suggest that each 
repeat would behave as an independent module, and unfold independently of the 
adjacent repeats. This is due to the fact that the repeats are stacked against each 
other. These repeats are stabilised through local and short-range interactions 
with respect to the sequence positions, unlike globular proteins that are 
stabilised by long-range contacts of distant residues (Mosavi et al., 2004). It 
would be expected that the unfolding events will involve a population of 
intermediates. However, thermodynamic data and folding studies on ankyrin 
domain in Drosophila Notch2 receptor (Zweifel & Barrick, 2001)  and in rat 
myotrophin (Lowe &Itzhaki, 2007) .suggest otherwise. The studies reveal that 
the ankyrin domains adopt a cooperative unfolding behaviour and unfold in a 
two-state fold manner. 
However, the unfolding of the ankyrin domain using the thermal-fluorescent 
method did not show a two-state transition. The melting profile indicated more 
than one unfolding event. This was irreproducible and varied with different runs 
in same buffer and salt conditions. This could be explained in several ways. The 
first repeat is partially unfolded and disordered, and only when it binds to CSL, 
the transcription factor, does it adopt the unique ankyrin fold. This would 
interfere with the measurement. Another possibility is that the fluorescent dye 
can bind to individual repeats at the same time and each repeat will act as an 
individual domain, appearing as multi-state folding. 
The aim of this screen was to find an optimum condition that stabilises the 
structural conformation of the protein, particularly the first unfolded repeat. 
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Screening with buffers at low salt concentration did not stabilise the protein and 
gave the same melting profiles as the original buffer. Increasing the NaCl 
concentration to 400 mM did not show much improvement, except when using 
CHES pH 8.5 as a buffer, where the protein was unfolded in a reproducible two-
state manner. High NaCl concentrations appear to have stabilised the protein as 
indicated by a higher Tm value. The salt effect in stabilising α-helical 
conformation has been studied recently (Xiong et al., 2009). It was found that 
various salts have the ability to induce the formation of α-helical structures in 
polyalanine peptides through different effects. NaCl was found to have both ion-
screening effects and specific ion-binding interactions. Ion screening reduces the 
electrostatic interactions between the protein charges depending on the ionic 
strength (Xiong et al., 2009). Specific ion binding can stabilise the α-helix due to 
preferential ion pairing between oppositely charged ions of similar charge 
density (Xiong et al., 2009). NaCl could have the same affect on the ankyrin 
domain, inducing α-helical conformation in the first repeat when it is unbound in 
solution. 
Another explanation for the stabilisation of the ankyrin domain in CHES buffer 
and high salt concentration might be the optimisation of the dielectric constant 
of the solution so that the SYPRO® orange dye can bind only to one ankyrin 
repeat.  
 
3.2.5    Screening of Fragment Library 
3.2.5.1 Materials and methods 
The fragment library is composed of about 1200 compounds. The fragments were 
dispensed in 96-well thin-walled plates (Bio-Rad) and sealed with caps (Bio-Rad). 
Solutions of 5 mM fragment and 5% DMSO as control were added to make a 100 
µl final volume. The solutions were prepared as shown in table 3.3. The plates 
were heated in an iCycler iQ Real Time PCR Detection System (Bio-Rad) in the 
same manner as described in section 3.2.4.1. 
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 Table 3.3 The composition of the fragment and control wells showing the final 
concentration value in brackets 
 
                                                            Fragment well                      Control well 
                                Fragment                  5 ul (5mM)                                  - 
                                DMSO                              -                                      5 ul ( 5%) 
                                Protein                      8 ul (10 uM)                        8 ul (10 uM)         
                               SYPRO orange         25 ul (1:250)                     25 ul (1:250)  
                                  DDT                           5 ul  (5 mM)                      5 ul (5 mM) 
                               CHES pH 8.5             10 ul  (10 mM)                  10 ul  (10 mM)    
                                 NaCl                          47 ul (400 mM)                47 ul (400 mM)        
            
3.2.5.2 Results and discussion 
The melting profiles of the ankyrin domain were monitored in presence and 
absence of the fragment compounds. In the presence of 5% DMSO, the protein 
unfolded in a two-state manner and showed an average Tm value of 43°C 
indicating that the DMSO at this concentration did not have any detrimental 
effects. Each melting curve was investigated individually to confirm its two-state 
unfolding behaviour. The melting curves showed some irregularities in the 
temperature range (25 -35 °C); this could be due to the introduction of bubbles on 
sampling. This region was discarded on measuring Tm.  Although each well 
contained solutions of identical composition apart from the fragment compound, 
there were variations in the fluorescence intensity. This may have resulted from 
variations in liquid handling, quenching effects of some fragments, bubbles again 
introduced in the solutions, or the non-uniformity across the CCD camera. Yet, 
these variations did not affect the results, as each Tm was measured 
independently in every unfolding curve. Calculating the derivatives of the 
melting curves helped in estimating and comparing Tm values, especially with 
small ∆Tm. The Excel macro sheet for analysing data was prepared by Dr. 
Duncan Scott (Department of Chemistry, University of Cambridge). 
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For simplicity, each fragment was designated a code number; the first part 
indicated the plate number and the second part the fragment position in plate. 
Each plate contained 72 fragments and controls were added in each plate and for 
every run.  
Positive hits were identified as fragment compounds that caused a shift in Tm by 
0.5 °C or more. This was taken to indicate that the fragment is binding and 
stabilising the protein. The final number of hits was 36 out of a library of 1201 
compounds giving a hit rate 2.99 ≈ 3 %. This figure is comparable to the hit rate 
generated by screening a traditional druggable enzyme target using the same 
fragment library (hit rate 3.25 %) (Leonardo Silvestre, personal communication). 
The hit rate can give an indication of the druggability of the target. Although 
protein-protein interfaces have been emerging as targets for drug discovery, 
their druggability is expected to be lower than other traditional targets using 
HTS libraries for screening. That can be due to fact that large molecules are 
difficult to accommodate small cavities found at protein-protein interfaces. 
Whereas smaller fragments can occupy these small pockets and hence enhance 
the hit rate. 
However, the hit rate could be affected by the sensitivity of the screening 
technique itself. There could be a number of false-negative hits using 
thermofluor-based assays due to fluorescence quenching by the fragment 
molecules. Screening the fragments at high concentrations in the mM range 
would increase the probability of the excited molecules interacting with each 
other and would reduce the intensity of fluorescence. The presence of impurities 
and increasing temperature can contribute to fluorescence quenching as well.  
Different fragments from the library had different effects on the protein. One 
group stabilised the protein and caused a positive ∆Tm, a second group 
destabilised the protein decreasing its Tm, a third group precipitated the protein, 
and a fourth group had no effect. The first group, which was considered as a 
positive hit group, was analysed and further classified according to similar 
structural features. There are five subgroups that could be identified through 
their common scaffolds (Figure 3.9). 
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   11B7   ∆Tm= 3.75 °C                                                                  11B8  ∆Tm= 3.25 °C     
 
  
                                                                                           
  11D02   ∆Tm= 0.75 °C                                                           11E06   ∆Tm= 1.75 °C                                                          
      
11C02      ∆Tm = 1 °C, 2°C          
Figure 3.3 The thermal unfolding curves of the fragments11B07,11B08, 11D02, 11E06 and 11C02 
. Figures on the left hand represent the native curves. Figures on the right represent the 
corresponding derivatives of the melting curves.  
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   12B2      ∆Tm = 1.25 °C                                                                  12B5   ∆Tm =2.5 °C, 1 °C 
                                                                          
   
               12C3     ∆Tm = 2.25 °C , 2 °C                                  12C5     ∆Tm =2.25 °C   , 2.5 °C                                             
                                                          
NH2N
 
 
12E3 ∆Tm=1.5 °C                           12E5 ∆Tm = 3 °C    3.5 °C                          12E6   ∆Tm= 2.25  °C         1 °C      
                                     
Figure 3.4 The thermal unfolding curves of 12B2, 12B5, 12C3, 12C5, 12E3, 12E5, 12E6. Figures 
on the left hand represent the native curves. Figures on the right represent the corresponding 
derivatives of the melting curves. 
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      12F2   ∆Tm= 1.25 °C                    12F3   ∆Tm= 2.5  °C , 1 °C                    12F7     ∆Tm= 1  °C                    
                                                         
 
 
 12G04   ∆Tm= 1.25 °C             12G05   ∆Tm= 2.5 °C,2 °C             12H05   ∆Tm= 2.5 °C  , 2.5  °C                
                                          
          
      13A8   ∆Tm= 0.75    °C              13A9   ∆Tm= 3 °C                      13A11 ∆Tm= 1.25 °C      
                                                                 
 Figure 3.5 The thermal unfolding curves of 12F2, 12F3, 12F7, 12G4, 12G5, 12H5, 13A8, 13A9 and 
13A11. Figures on the left hand represent the native curves. Figures on the right represent the 
corresponding derivatives of the melting curves. 
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           13G10  ∆Tm=  2.5 °C,1.5 °C                              13H07   ∆Tm= 0.75 °C  . 0.5°C            
 
              
14A06     ∆Tm=  1.5  °C              14B04   ∆Tm=  1.75  °C              14C04   ∆Tm=  1.75  °C                     
                                                
     
Figure 3.6 The thermal unfolding curves of 13G10, 13H07, 1406, 14B04, 14C04. Figures on the 
left hand represent the native curves. Figures on the right represent the corresponding 
derivatives of the melting curves. 
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  1A02, ∆Tm= 1.5 °C                         1B02, ∆Tm= 1°C                         1C02, ∆Tm= 1°C 
                                                       
 
 
   2A08          ∆Tm= 1  °C                                                  2B11   ∆Tm= 1.5 °C                                                   
                      
 
 
 
Figure 3.7 The thermal unfolding curves of 1A02, 1B02, 1C02, 2A08, 2B11. Figures on the left 
hand represent the native curves. Figures on the right represent the corresponding derivatives of 
the melting curves. 
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 03B11   ∆Tm= 0.75 °C                03G02  ∆Tm=  1.5 °C                 03H03, ∆Tm= 1 °C                     
  
                                                                       
             04D03    ∆Tm= 0.75 °C                                                04E03   ∆Tm= 0.75 °C 
       
                                       9F07  ∆Tm= 1 °C        
Figure 3.8 The thermal unfolding curves of 3B11, 3G02, 3H03, 4D03, 4E03 and 9F07. Figures on 
the left hand represent the native curves. Figures on the right represent the corresponding 
derivatives of the melting curve 
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(a)                                     (b)                                              (c)                  
                                                                         
                                                (d)                                         (e) 
                                                 R                                  R 
 
Figure 3.9 Classification of fragment hits according to distinctive chemical structure. Five main 
classes were found to bind by fluorescent-based thermal shift screening. These include: (a) benzyl 
derivatives, (b) fused bicylic rings, (c) biaryl compounds, (d) phenyl derivatives, and (e) 5-
membered heterocyclic rings.   
 
The first subgroup consists of 13 fragments with a common phenyl ring linked 
through one atom to a heterocyclic 5- or 6- or even 7-membered ring, which could 
be either aliphatic or aromatic. The preference for binding to this scaffold could 
be attributed to a certain degree of flexibility inferred by the one-atom bridge. 
Although the ∆Tm values correlate with the binding affinities, ranking and 
comparing should not be solely based on ∆Tm   values, as affinity is dependant on 
binding enthalpy as described in the following equation (Lo et al., 2004):  
ܭ୐୘୫ =  
exp ൜−∆H୳୘଴ / R[
1
T୫ −
1
T଴ ቃ +  ∆C୮୳
୘଴  /R ቂln ቀT୫T଴ +
T଴
T୫ − 1ቁቃ}
[L୘୫]
 
ܭ୐୘୫ = ligand association constant at Tm 
Tm    = midpoint of protein unfolding transition in presence of ligand 
T0    = midpoint of protein unfolding transition in absence of ligand 
∆H୳୘଴ = enthalpy of protein unfolding in the absence of ligand at T0 
∆C୮୳୘଴ = change in heat capacity on protein unfolding in the absence of ligand 
 [L୘୫] = concentration of free ligand at T୫ 
   R   =   gas constant 
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However, as the binding enthalpy data was unavailable for any of the fragments, 
ranking was conducted among fragments of the same chemical structural classes 
assuming they have the same binding enthalpy. The compound that contained a 
7-membered 1,4-diazepan ring was found to have the highest ∆Tm within this 
group, suggesting that the 1,4-diazepan ring could be a favourable ring system. 
The second subgroup consists of 6 bicyclic fused rings where the phenyl ring is 
the common feature. According to the ∆Tm values, they have comparable ∆Tm and 
it was difficult to rank them. It appeared there is no preference for a particular 
bicyclic pair of rings.  
The third subgroup consists of 14 biaryl compounds, where at least one ring is a 
phenyl or pyridyl ring. These compounds are similar to biphenyl systems, which 
were found to be the most preferable moiety to bind to proteins as shown in a 
previous study (Hajduk et al., 2000). The biaryl ring systems may behave like 
biphenyls, which can be involved in many interactions with proteins due to their 
flexibility that allows them to accommodate to protein surfaces (Hajduk et al., 
2000). This could explain the higher hit rate than other chemical scaffolds. 
The phenyl rings was found to be the least preferred moiety that binds to 
proteins as shown previously (Hajduk et al., 2000). However, the fourth 
subgroup includes 10 phenyl derivatives and a piperidine ring. The size and 
shape of phenyl and 6-membered rings could be more suitable for binding to 
shallow protein surfaces and targeting protein-protein interfaces that tend to be 
more lipophilic, even with less interactions than larger and more complex ring 
systems (Figure 3.10). 
The final subgroup is the smallest and least complex, consisting of 5-membered 
rings. It includes only 5 compounds, the imidazole ring being the most 
favourable. These small rings might be mimicking the side chain of histidine 
amino acid and capable of binding to shallow and flat pockets across the 
interface(Figure3.11).                                                                              
                         
                                                                                                                                                  
                   A            R1               R2                      R3                                                    dTm                                                                                                                                             
                                                                                                                                                            
 
Table 3.4 A table of the third subgroup, ring (B) is a phenyl ring 
unless mentioned otherwise. 
       F            H                 H                                  1/1 
   -CN          H                H                                  0.75/1   
  -CH2OH       H                H                                0.75/1 
                                          
N
F
F
F
                         0.75/0.5 
                                                                     0.85 /0.5 
         H              NH2                  H                               1/1 
    H                   H               NH2                                       1.5 
       H                   H               -OCH3                             1.25/2 
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R1                                        X                     R2                             R3                    ∆Tm                              R1                                        X                     R2                             R3                    ∆Tm          
                  C                     -CH2NH2                        H                 2.5 °C                                               C                     H                         H         1.75(1.5) °C                        
                  C                         NH2                              H             2.75(2.5) °C                                        C                     H                         H         2.5(2)  °C                            
                  C                           H                       -CH2NH2            2.5(1)°C                             C                     H                         H         1.25°C                            
                  C                     -CH2NH2                        H               2.5(2.5) °C                           C                     H                         H            2 °C                               
                  C                           H              -CH2NHCH3             2.5(2) °C                                             S                      H                         H       0.75(0.5) °C                             
                C                           H             -CH2NH2              1.75(1.5) °C                               O                      H                        H     0.75(0.5) °C 
              C                     -CH2NH2                        H             3(3.5) °C                                       C                     H                         H      1.75(1.5) °C      
                                                                                                                                                                   C                     H                         H       2.5(2)    °C      
Table 3.5  First subgroup of  benzyl derivatives 
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Table 3.6 Second group of bicyclic derivatives   
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Figure 3.10   The fourth subgroup of phenyl derivatives and the corresponding ∆Tm values. 
 
                         
 
 Figure 3.11 The fifth subgroup of five-memebred ring derivatives and the corresponding ∆Tm 
values. 
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The second group, which included those fragments that destabilised the protein, 
can be further sub-grouped according to common functional groups rather than 
common scaffolds, which were not observed amongst the positive hits. The first 
subgroup was found to contain a carboxylic acid functional group (-COOH), 
attached to aliphatic and aromatic heterocyclic rings, whereas it constituted 43.8 
% of this group. None of the positive hits had a -COOH group, suggesting that it 
could have a destabilising effect. The -COOH group has previously been found to 
bind to various protein targets, particularly to DNA- or RNA- binding proteins 
(Hajduk et al., 2000). In addition, the -COOH group is a common “chemical 
handle” that is designed for further chemical elaboration of small fragments. 
However, the carboxylic acid containing compounds will likely be ionised at pH 
8.5, the pH at which the screening is carried out and the electrostatic potential of 
the ankyrin domain interface is negative. The negatively charged -COOH could 
destabilise the protein.  
 
The second subgroup, numbering seven compounds, had a trifluoromethyl group, 
which often leads to substituted compounds being strong acids. It is incorporated 
in many drugs and pharmaceuticals, as it is capable of replacing the methyl and 
chlorine groups (Yale, 1959). It is a highly electronegative group that lies 
between chlorine and fluorine and causes destabilisation of the protein (True et 
al., 2003). Although some of positive hits had the less electronegative chlorine 
group. 
In addition to those groups that were found to destabilise the protein, there 
appear to be particular ring systems that are not favourable for binding. Some of 
the molecules that caused negative ∆Tm contained morpholine, thiazole and 
oxygen containing heterocyclic rings, whereas these ring systems were mostly 
absent from the positive hits.  
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3.3 Conclusions 
The quality of positive and negative hits depends on the design of the fragment 
library, the nature of the target and the sensitivity of the technique used in 
screening. Although having compounds that allow for further optimisation and 
elaboration by introducing “chemical handles” enhances the ease of moving from 
hit to lead, it has some limitations. As has been found here, the –COOH or nitrile 
were unfavourable groups and precipitated or destabilised the protein.   
Targeting protein-protein interactions may require a more tailored fragment 
library of scaffolds similar to amino acid structures that could mimic peptides or 
proteins. The hit rate is also influenced by the nature of the screening method; 
the ability to identify false-positives and false-negatives would minimise such 
variations. The fluorescent-based thermal shift assay used here, is greatly 
affected by the fluorescent quenching properties of the fragments.  
 
Although this screen could be considered a yes/no answer screening method, 
especially in the absence of binding enthalpy values, it can still give an 
indication of the type of molecular scaffolds that the protein target prefers to 
bind. These positive hits could be of no significance, as they might be binding in 
locations other than the binding sites. However, they can still help in identifying 
functional groups that should be avoided in hit-to-lead optimisation. 
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Chapter 4 
 
Structural Characterisation of Ankyrin-
Fragment Complexes 
 
4.1 Introduction 
Structure-based drug design (SBDD) relies to an increasing extent on 
information obtained from crystallography. It comes as no surprise that the 
increase in the number of structures in the Protein Data Bank is associated with 
an increase in the number of protein-ligand structures. Crystallography has 
become an integral part of many drug discovery projects, and that does not only 
include later stages of lead optimisation, but also protein structures solved by X-
ray crystallography used for target assessment and validation. In addition, 
fragment screening has employed crystallography for picking up hits in 
preliminary screening, an approach that has been pioneered by Abbott and Astex 
therapeutics. 
Protein-ligand interactions derived from crystal structures assist in developing 
hits to leads and drug-like molecules through an iterative process. The early 
analysis of protein-ligand structures facilitates the design of easily synthesised 
scaffolds and the elimination of toxicophores. Early apo-protein crystal 
structures permit optimisation of the crystals in order to provide a system 
amenable to SBDD. 
4.2 Optimising a crystallographic system for SBDD 
Selection of a successful SBDD system starts with identification of the protein 
form that truly represents the biological target. Ideally, full-length human 
proteins are the targets of choice. However, large amounts of protein are 
required for iterative SBDD steps and in poorly expressed proteins a 
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miniaturisation of the protein can be the solution, for example by utilising 
catalytic or receptor domains for flexible multi-domain proteins. Homologues 
that show high expression levels and high sequence similarity at the site of 
interest provide an alternative approach. In some cases, mutations in 
homologous proteins can be designed to mimic a human binding site creating a 
humanised form, or proteins can be engineered to enhance solubility and 
stability. The production of a reproducible form of the protein using such 
approaches can avoid batch-to-batch variation that is unfavourable in long 
repetitive SBDD processes. 
Although obtaining crystals is often the bottleneck for elucidating protein 
structures, this does not seem to have been the case in drug discovery, possibly 
because most companies have worked on well characterised families of protein 
kinases, phosphatases, aspartic proteinases and so on. The quality of the 
structure is critical for moving from a hit to lead and the evaluation of crystal 
structures for drug discovery has been widely discussed (Anderson, 2003).  The 
resolution should be better than 2.5 Å, to allow correct placement of residues and 
atoms of proteins and ligands in electron density maps. This is important for 
characterising the main interactions based on accurate distances. Crystal 
structures of poorer resolutions can be detecting the presence of ligands or other 
molecules that are in the crystallisation conditions. However, these structures 
should be assessed carefully if they are to be used for drug design.  
The R factor and Rfree value should not exceed 28% and preferably 25%. The 
conformation of the ligand molecules should be evaluated as well; the bond 
length deviations should not exceed 0.015Å, and bond angles deviations not more 
than 3° (Anderson, 2003). The thermal motions/disorder of the atoms is indicated 
by the B-factor or temperature factor. The value of the B-factor should not exceed 
the average for the molecule; otherwise it could indicate an error in the atomic 
positions (Anderson, 2003). There is often an assumption that the protein model 
is correct without realising that it is the personal interpretation of the data by 
crystallographers. Following the recent retraction of crystal structures (Chang et 
al., 2006) there has been a requirement by the PDB (Protein Data Bank) to 
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deposit structure factors together with coordinates, so allowing validation of 
structures in the PDB by non-authors. Even with high-resolution structures, 
some regions of poor electron density can be interpreted in different ways. This is 
particularly important if these regions are interesting binding or catalytic sites. 
Another limitation that could be found even with structures of reasonable 
resolutions is the assignment of nitrogen and oxygen in aspargine and glutamine 
residues. The placement of these atoms in these residues could be difficult as it is 
not possible to distinguish by the electron density. In addition, assigning the 
correct tautomeric state of histidine and other ligands is problematic. However, 
judgments can be made according to the hydrogen-bond environment after 
adding solvent and water molecules. The same problem occurs with ligands. 
Placement of nitrogen in asymmetric pyridine or pyrrole rings is often 
problematic and can affect the interpretation of possible interactions and the 
way to proceed with elaboration and optimisation. 
The crystallisation conditions are often different from those of other biophysical 
screening methods and biological assays. For instance, the pH can differ and 
affect the conformations of both protein and ligand. Even small differences in pH 
can alter the ionisation states of ligands and protonation of the protein, which in 
turn affects the binding mode or even inhibits binding altogether. It is important 
to consider the compatibility of the methods used, though it is often difficult to 
achieve since every technique may require optimisation of screening conditions 
independently. 
In this chapter, I describe the crystallisation of the ankyrin domain, my attempts 
to produce protein-ligand structures, and the results and implications of these 
experiments.  
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4.3 Materials and methods 
4.3.1 Crystallisation and optimisation 
The protein was concentrated to 10 mg/ml in a buffer constituting of 50mM Tris 
pH 8 and 50mM NaCl. The ankyrin domain was crystallised in 0.9 M 
(NH4)2HPO4, 0.2 M NaCl and 0.1 M imidazole (pH ∼8.5) as precipitant as 
reported previously (Ehebauer et al., 2005) and crystallisation was optimised 
around these conditions, which proved to be reproducible. 
a) The ankyrin domain was screened using different crystallisation screens: 
Classics, SM1, PEG, PH clear I, PH clear II and PEG I. Crystals were 
formed in various conditions and screening grids around initial conditions 
were designed for optimising these conditions. 
b) The ankyrin domain was prepared in another buffer 10 mM CHES pH 8.5, 
400 mM NaCl and screened again using PEG1, PH clear I, PH clear II. 
For microseed matrix-screening, the seed stock was prepared by crushing 
crystals formed in conditions 0.7 M (NH4)2HPO4, 0.2 M NaCl, and imidazole pH 
8. This was reconstituted in 50 µl of the crystallisation buffer, mechanically 
homogenised by vortexing, and the seed stock was frozen at -20 °C. Seeding was 
carried out by adding 0.2 µl of screening solution, 0.1 µl of seed stock and 0.3 µl 
of protein at 10 mg/ml. 
     
 4.3.2 Soaking and Co-crystallisation 
i)  Crystal Soaking: 
    Different approaches for soaking were used: 
 a) Solutions of the fragments in the crystallisation buffer were prepared at 
different concentration ranges; 10 mM, 20 mM, 50 mM, 100 mM, 200 mM and 
500 mM. 
 b) Soaking times varied between 30 seconds, 10 minutes, 30 minutes, 1 hour, 2 
hours, 4 hours, 24 hours, one week and up to 3 weeks. 
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 c) Stepwise soaking was carried out by gradually increasing the fragment 
concentration in order to minimise the effect of DMSO. 
d) Fragment solutions were prepared in solutions of the primary screen, the 
crystals were transferred by gradually changing the conditions of the original 
crystallisation solution to the final condition 10mM CHES pH 8.5 and 400 mM 
NaCl. 
e) Cross-linking of the crystals with 25% glutaraldehyde: 
 Crystals were transferred to 1 ul drop containing the crystallisation buffer on a 
cover slip. A microbridge containing 25% glutaraldehyde was placed in a well. 
The cover slip was then placed over the well to expose the crystal to the 
glutaraldehyde via vapour diffusion for 1 minute. The crystals were then 
transferred to fragment solutions of a stabilising solution containing higher 
precipitant and lower salt content. The fragments were at a concentration of 
100mM and soaked overnight. 
f) The solutions were prepared with and without cryoprotectant. Glycerol (25%) 
was used as a cryoprotectant. 
g) Stabilising solutions were prepared by increasing salt concentrations or 
adding xylitol, which was added at a concentration 4% and the fragment 
concentration was 50 mM. 
ii) Co-crystallisation: 
The protein was incubated with the fragment at different concentrations: 50mM, 
100 mM and 250 mM overnight at 4 °C and crystallised using the original 
conditions. 
 
 
 
 
67 
 
4.3.3 Data collection and processing  
 
Several data sets were collected at various synchrotrons at Diamond, ESRF and 
ALS. Datasets of 120 images were collected to obtain completeness. The images 
were indexed and integrated by MOSFLM, then scaled using SCALA program, a 
part of the CCP4 package. The structures were solved by molecular replacement 
using the program PHASER and the coordinates of the Notch ankyrin domain 
(PDB 1YYH) as a probe. The σA-weighted 2Fo-Fc and Fo-Fc electron-density maps 
were visualised to allow rebuilding and refitting using Coot.  
 
4.4 Results and discussion 
4.4.1 Crystallisation 
Structures of protein-ligand complexes can be obtained by soaking or 
cocrystallisation. Protein crystals comprise 30% to 80% solvent (Matthews, 
1968), which is found in channels determined by the crystal lattice network 
(Vilenchik et al., 1998). The ability to soak ligands depends on the diffusion of 
compounds in the solvent channels. The availability of crystal forms with 
different space groups is helpful in overcoming problems arising from occlusion 
of binding sites by intermolecular interactions in the crystal lattice. The ankyrin 
domain was originally crystallised in the space group P65 in two different 
conditions (Ehebauer et al., 2005; Nam et al., 2006). In this crystal form, the 
interface that is involved in the interaction with CSL and MAML is exposed to 
the solvent channels and is not blocked by the crystallographic contact residues 
(Figure 4.2). This crystal form is likely compatible with diffusion of fragments to 
the protein interaction sites. However, the lack of distinctive binding pockets to 
target and knowledge of any known or natural ligands make it hard to predict 
where small fragments bind. The ankyrin domain was screened again for 
different crystal conditions in search of other space groups that could improve 
soakability of the crystals.  
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 Figure 4.1 Crystal hits of the ankyrin domain found in different screens. 
 
Figure 4.2 A cartoon representation of the ankyrin domain showing symmetry related molecules 
of the crystal structure (PDB 1YYH). The dotted circle highlights the interface which the ankyrin 
participates in protein-protein interactions in the ternary transcription complex with CSL and 
MAML. The crystal contacts in this space group with other symmetry related molecules do not 
interfere with the binding interface. (The symmetry molecules that are only in contact with 
ankyrin molecule (in orange) are shown for simplicity). 
Ank in 50mM TrispH 8 50 mM NaCl 
    15% (w/v) PEG 20,000 (PEG 1)   
Ank in 10mMCHES 400mMNaC 
25 %(w/v) PEG2000 MME(PEG1)      
Ank in 50mM TrispH 8 50 mM NaCl 
1M LiCl  0.1 M Bicine pH 9  (PH Clear II)      
Ank in 50mM TrispH 8.50 mM NaCl 
0.05 MgCl2, 0.01 M MES pH 6.5, 10%isopropanol, 
5%PEG 4000 (Matrix seeding) 
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Three approaches were used for screening: 
a) The ankyrin domain was screened in the original buffer of 50 mM Tris pH 
8 and 50 mM NaCl  
and also in 
b) 10 mM CHES pH 8 and 400 mM NaCl, which was found to stabilise the 
protein as it has been demonstrated in the buffer screening assay using 
the fluorescent-based thermal shift screening method. A more stable form 
of the protein would improve the quality of crystals. 
     c) Microseed matrix screening is an established method that has been used to 
increase the crystallisation hit-rate (D'Arcy et al., 2007). Seed stocks were 
prepared by mechanical homogenisation through vortexing. Introducing seeds in 
the crystallisation conditions can induce a nucleation event. For the ankyrin 
domain, seeds were prepared from crystals that were formed in condition 0.7 M 
(NH4)2HPO4, 0.2 M NaCl, and imidazole pH 8. 
Crystals were formed in various conditions (Figure 4.1); some of which appeared 
to be of different space groups judging by their crystal morphology. However, it 
was difficult to reproduce these conditions and hence determine their space 
groups. And in an iterative SBDD process, it is essential to be able to easily 
reproduce crystals. 
Crystals formed in conditions 0.7 M (NH4)2HPO4, 0.2 M NaCl, and imidazole pH 
8 and in 16 % (w/v) PEG 8000, 0.2 M NaCl and 0.1 M CAPS pH10.5 were used 
for soaking. 
 
4.4.2 Soaking and Co-crystallisation 
The electron density of the ligand or fragment is visible if the ligand occupies at 
least 30% of the binding sites as suggested in an earlier study (Wu et al., 2001). 
It is important to understand how the protein binds with the ligand to reach 
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equilibrium. The fraction Y of protein (P) that binds with the ligand (L) to form a 
protein-ligand complex (PL) with a dissociation constant, Kd, can be derived from 
the following (Danley, 2006):  
    Kd =    [୔][୐][୔୐]                             (1) 
     Y = [୔୐][୔]ା[୔୐]                            (2)  
From the previous equations (1) and (2), Y can be expressed as a function of Kd as 
following: 
     Y = [୐]୏ୢା[୐] 
It can be concluded that the dissociation constant and the ligand concentration 
are the factors that determine the binding equilibrium. This should be 
considered when designing the soaking experiments regarding soaking times and 
ligand concentrations in the soaking solutions. This would be primarily affected 
by the ligand solubility. A major problem for these hydrophobic small fragments 
is the solubility in aqueous buffers where most of the screenings are carried out. 
In crystal soaking, it is the fraction of the compounds that is soluble that 
actually can diffuse and move freely in the solvent channels. 
The fragments are solubilised in 100% DMSO at 1M concentration as a stock 
solution. Solutions of fragments were prepared by dilution to various 
concentrations with various DMSO amounts. The concentration of DMSO should 
not exceed 20%, and typically not more than 10%. The DMSO can improve the 
solubility of some of the fragments; however DMSO can have deleterious effects 
on the crystal packing of the crystal lattice leading to reducing the quality of 
crystals or can even cause the crystals to crack and dissolve. The soaking was 
monitored over a time-course and step-wise soaking was used by gradually 
increasing the fragment concentration when higher concentrations of fragment 
were used. 
Fragments that were soluble in the crystallisation buffer were directly added to 
the soaking solutions without solubilising in DMSO. The crystals used for 
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soaking were formed in two conditions; one contained PEG 8000 which can 
improve the fragment solubility.  
The crystals were soaked with fragments that were hits in the screening by the 
fluorescent-based thermal shift assay. This screening was carried out in a buffer 
containing 10mM CHES pH 8.5 and 400 mM NaCl, which differs from the 
crystallisation conditions. The binding of fragments is affected by their 
protonation and conformation states, and by the constituents found in solution. 
The fragments were dissolved in the screening buffer to maintain the same 
conditions that seem to be favourable for binding. The crystals were transferred 
from their original crystallisation buffer to the fragment solution by gradual 
buffer exchange in order to keep the crystal intact. This could maintain the same 
state of the fragments, but the assumption is that the protein is maintained in 
the conformation determined by the crystal contacts. 
Different “stabilising” solutions are used to stabilise the crystal and protect it 
from damage. These solutions often contain the same composition as the 
crystallisation buffer but with increased concentration of one or more of the 
reagents. Cross-linking with glutaraldehyde is also used to stabilise crystals 
against mechanical stress during freezing (Lusty, 1999). It was used here to 
stabilise the crystal against the damaging effect that can be caused by 
introducing an organic solvent as DMSO or by the fragment itself. 
Crystals can also be stabilised by the addition of xylitol to the fragment solution 
in a concentration 2-5%; xylitol can improve the solubility of the fragment as 
well.    
Co-crystallisation is another method used to obtain protein-ligand structures 
where the ligand is incubated with the protein prior to crystallisation. This may 
be suitable for ligands with poor solubility or proteins that tend to aggregate. 
However, the ligand can alter the solubility of the protein, requiring screening 
for conditions other than the original. Sometimes each individual inhibitor 
requires screening making it rather tedious, but it has the advantage of allowing 
for conformational changes that might occur during ligand binding. The 
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conformational changes are restricted when soaking, particularly when another 
crystal form cannot be found. If possible, it is preferable to obtain structures by 
both soaking and co-crystallisation. The binding mode in solution obtained from 
co-crystallisation may vary than that in the soaked form.  
 As described above, different soaking and co-crystallisation methods have been 
utilised in an attempt to elucidate the binding mode of the fragment hits 
previously identified in the initial screen (Chapter 3). One problem that was 
encountered during the soaking was the cracking and dissolving of the crystals, 
which greatly affected the crystal quality. Some crystals did not diffract at all 
and others diffracted at very low resolution. The cracking of the apo-crystals 
could be due to a deleterious effect of DMSO or an indication of conformational 
change induced by ligand binding that is incompatible with the crystal packing 
Several datasets were collected. Data from crystals that diffracted at a resolution 
worse than 2.7 Å was not collected. The resolution of the collected datasets 
ranged between 1.9 Å and 2.7 Å and the structures were solved as described 
previously. The 2Fo-Fc maps were visualised using Coot software to search for any 
unmodelled electron density. The binding modes of only two fragments were 
elucidated and there was no evident electron density for the other fragment hits. 
This could be due to the low occupancy of the weakly binding fragments 
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Table 4.1 Data collection and refinement statistics ankyrin-fragment structures. Values in 
parenthesis are for the highest resolution shell 
 
 
 Fragment 12C05 Fragment 9F07 
Space group  
                                   
Unit cell  
                                                         
Resolution                            
     
Completeness 
                           
    Rsym 
 
    Average I/s(I) 
 
    Number of unique reflections     
 
    Wilson plot B factor  
                  
    Refinement 
             Rcryst                                    
                   Rfree                                               
        
 Molecule per asymmetric unit 
 Number of ligand molecules    
 
 Estimated co-ordinate error      
         
        RMSD bonds                           
        RMSD angles                          
P65 
                                                                                       
a=b=97.94 Å   c=109.44 Å                
α = β = 90°,    γ= 120°     
 21.20  2.53 Å   (2.40- 2.40 Å) 
 
99.18 %      
 
5% (27.5%) 
 
 6.6 
 
21935 
 
 
34.53 %   
 
22.0 %                          
30.3 %                                              
     
 
2 
 
1 
 
0.30 Å 
 
0.024Å 
 2.17° 
                                                          
P65 
 
a=b= 97.43 Å  c= 110.23 Å 
α = β = 90°,    γ= 120°   
33.69 -2.42 Å  (2.30 -2.30 Å ) 
 
99.98 %     
 
3.5 %   (22.20 %) 
 
7.3 
 
22060 
 
 
50.93 %     
 
23.90 % 
30.95 % 
 
 
2   
 
1 
 
0.31 Å 
 
0.026 Å 
2.42°                     
 
 
 
 
 
Rsym =Σh|Ih – (I)|/ ΣhΣIh, where Ih is the intensity of reflection h and (I) is the mean intensity 
of all symmetry related reflections. Rcryst =Σ|| Fobs|-| Fcalc||/Σ| Fobs|, where Fobs and 
Fcalc are observed and calculated structure factor amplitudes. Rfree as for Rcryst using a 
random subset of data excluded from the refinement, 5% of the total dataset was used. Estimated 
co-ordinate error based on R value was calculated using Refmac 
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4.4.3 The first crystal structure 
The first structure was solved at a resolution 2.5 Å with two molecules in the 
asymmetric unit. The electron density for the first ankyrin repeat in both chains 
was very poor; the first 52 residues in chain A and first 51 residues in chain B 
were unmodelled. The fragment was found located in two different sites (Figure 
4.2).  
  The first binding site for fragment 12C05 
The first site of the fragment 12C05 was positioned between the upper helices of 
repeats six and seven. Although the fragment 12C05 is sandwiched between the 
two protein molecules in the asymmetric unit, it is held by a number of 
interactions (Table 4.2). It appears to be stabilised by weak hydrogen bonds, a 
salt bridge, and a π-π interaction. The weak hydrogen bonds C-H-O are formed 
between aspartate 2109 and glutamate 2076 side chains. The pKa values of 
aspartate and glutamate are 3.9 and 3.3, respectively. That makes them 
negatively charged at the pH of the crystallisation conditions (pH 8.5). However, 
at a resolution 2.5 Å it is impossible to assign the negatively charged oxygen 
atom, so it is assumed that it is the atom that is involved in a hydrogen bond 
predicted on basis of distances. The weak hydrogen bonds have variable 
geometries, as the distances are shorter when involved with main chain than 
with side chain donors and acceptors. The hydrogen-bond distance ranged from 
≈2.8 Å to ≥3 Å (Figure 4.3). 
Salt bridges are important interactions that have been observed in many 
protein-ligand structures. The pKa for the nitrogen atom in the pyrrolidine ring 
was not provided by the supplier (Maybridge), so it was calculated using an 
online website calculator http://sparc.chem.uga.edu/sparc/. It was predicted to be 
9.36, which means it is positively charged at the crystallisation solution pH. It 
could be involved in a salt bridge interaction with the negatively charged oxygen 
of aspartate 2109. It is worth mentioning that these interactions were observed 
in high salt concentrations, suggesting that these interactions are specific. 
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Aromatic interactions play an important role in the stabilisation of proteins 
(Chakrabarti & Bhattacharyya, 2007). The phenyl ring is involved in a face-to-
face π-π interaction with the phenyl ring of tyrosine residue 2075 where the 
distance between the two planes is 3.5Å. 
 
Table 4.2 Summary of the interactions the fragment 12C05 forms at the first site 
Type of interaction                              Residue involved                        Distance 
Weak hydrogen bond                              D2109                                        2.76 Å 
Weak hydrogen bond                              E2076                                        3.06 Å    
 Salt Bridge                                             D2109                                        3.4   Å            
 π-π aromatic interaction                         Y2075                                        3.5   Å 
 
 
The electron density of chain B of the ankyrin domain was weaker and poorer 
than that of chain A. There was very little electron density of the fragment at the 
corresponding site in chain B and it was difficult to place the fragment. It is 
quite common to find only one ligand in monomers of multimeric proteins (Sevcik 
et al., 1991; Marcio Dias, unpublished). This could be the binding site being 
blocked by crystal contacts in one monomer, or the affinity being weaker due to 
different conformational restraints. The relative occupancies would also vary 
with the technique used, whether it was soaking or co-crystallisation of the 
ligands.  
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Figure 4.3 Figures showing the two sites the binding fragment 12C05. The interactions are 
shown in A) with residues D2109, E2076, D2109 and Y2075. B) Interactions of the fragment at 
the dimer interface N1984, H2019 and H2019.  In C) and D) electron density maps 2|Fo-Fc| at a 
contour level of 1σ showing the fragments at the two sites in A) and B) respectively                             
 
The second binding site for fragment 12C05: 
The fragment 12C05 was found binding in another site between the two protein 
chains in the asymmetric unit (Figure 4.3B). The interactions are mainly weak 
hydrogen bonds with residues N1984 in chain A and H2109 in chain B, and one 
interaction mediated through a water molecule. The carbonyl group of N1984 
side chain forms a weak hydrogen bond with a –C-H of the pyyrolidnyl group of 
the fragment. Another weak hydrogen bond through the alkyl-amino side chain 
of the fragment formed with –C-H of the imidazole ring of H2104. A water 
molecule mediates the interaction between –C-H of the phenyl ring of the 
fragment and the nitrogen atom of the H2019 imidazole side chain. Again, these 
interactions are suggested by the distances and assumptions made by assigning 
the nitrogen atoms in both the asparagine and histidine residues (Figure 4.3).  
   
A B
C D
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 Table 4.3 Summary of the interactions that fragment 12C05 forms at the second site 
  Type of interaction                              Residue involved                        Distance 
     Weak hydrogen-bond                             N1984                                    2.91 Å 
     Weak hydrogen-bond                             H2019                                    3.01 Å 
     Water-mediated bond                            H2019                            2.93 Å - 2.95 Å 
 
4.4.3.1 Implications of complex formation 
The crystal structure was superposed with the structure of ankyrin domain in 
the complex with MAML and CSL (PDB 2F8X). In the first site where 12C05 is 
binding to chain A, the fragment was found at the interface between ankyrin and 
MAML (Mastermind). In fact, the pyrollidine ring was found in the position 
where the arginine R40 of MAML lies. It seems that the nitrogen atom of the 
pyrollidine ring mimicks the guanidine group of the R40. R40 of MAML lies at 
the interface with ankyrin where it interacts with residues G2073 and D2109 of 
ankyrin through its guanidine group (Figure 4.4). The pKa of the guanidinium 
group is 12.48, making it positively charged at pH 8.5 of the crystallisation 
condition. The positive charge is delocalised as a result of conjugation between 
the double bond and the nitrogen’s lone pair. This allows it to form many 
interactions, mainly hydrogen bonds. It forms a hydrogen bond with the carbonyl 
group of G2073, and is involved in an ionic interaction with the side chain of 
D2109, as indicated by PICCOLO (Chapter 2). 
Mutational studies have been carried out to analyse the protein-protein 
interactions that are involved in the complex-formation (Del Bianco et al., 2008;  
(Deepti Gupta, unpublished). Single mutation of D2109 to alanine did not 
disrupt the complex-formation. The authors reached the conclusion that the 
stabilisation of the complex depends on numerous interactions rather than 
individual “hotspot” residues. The fragment 12C05 may seem to disrupt a single 
interaction across the interface, but that may not be sufficient to prevent the 
formation of the ternary complex. In addition, these fragments are weak binders 
with low affinities. However, further optimisation of the fragment could improve 
the affinity. 
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Figure 4.4 Implications of fragment 12C05 for complex formation. A) Crystal structure of the 
ternary complex shows a salt bridge interaction between R40 of MAML and D2109 of the ankyrin 
domain (PDB 2F8X) B) Superposed structure of the ankyrin domain with the bound fragment 
12C05 shows a salt bridge interaction between the fragment and the same D2109 of ankyrin 
domain. The ankyrin domain is in teal, MAML in orange and CSL in violet. 
 
4.4.3.2 Implication of dimerisation 
The ankyrin structure is a dimer with few crystallographic contacts. There have 
been conflicting views on the significance of dimerisation of the ankyrin domain. 
It was assumed that a dimeric ankyrin domain of Drosophila was merely a 
crystallographic dimer; as it was found as a monomer in solutions of different pH 
values and in different ionic strengths (Zweifel et al., 2003). However, yeast-
interaction-trap assays demonstrated that the ankyrin domain in Drosophila 
could be involved in homotypic interactions (Matsuno et al., (1997)). This 
confirmed earlier studies on the Glp-1 homologue of Caenorhabditis elegans that 
showed a homotypic interaction using constructs encoding ankyrin domain 
through yeast-two-hybrid assays (Roehl et al., 1996). Dimerisation of human 
Notch1 ankyrin in solution was also observed from small angle X-ray scattering 
(SAXS) data (Matthias Ehebauer, unpublished data).  Analysis of SAXS data for 
the Notch RAMANK (molecule consisting of the RAM region and the ankyrin 
domain) indicated a monomeric form (Matthias Ehebauer, unpublished data). 
This suggested that dimerisation is characteristic of the ankyrin domain only 
when expressed on its own and that it was unlikely to be of any biological 
relevance in complex formation and gene transcription. 
A B 
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However, recent studies have investigated the role of dimerisation in 
transcription of Notch target genes (Nam et al., 2007). These studies were based 
on evolutionary conserved regions in CSL-binding sites and on crystal contacts 
observed between ankyrin molecules. Dual CSL-binding sites in target genes of 
mammalian homologues were found to be conserved and oriented head-to-head. 
These sites, known as “sequence-paired” binding sites (SPSs), are separated by 
nucleotide spacers that vary in length according to species. The crystal-contact 
residues between ankyrin-ankyrin molecules in the complex structure (Nam et 
al., 2007) (Figures 4.5C and 4.5D) and in isolation (Ehebauer et al., 2005) 
(Figures 4.5A and 4.5B) were found to be evolutionarily conserved. These 
contacts are not involved in interactions with the other molecules of the ternary 
complex. These observations suggested a cooperative dimerisation assembly 
model for the Notch transcription complex on the target genes. This model was 
supported by mutational studies of the ankyrin-ankyrin contact residues and the 
impact of these mutations on transcription. The model proposes that after 
assembly of the Notch transcription complex, the complex dimerises on the 
target Notch genes on “sequence-paired” sites and switches on transcription in a 
dose-dependant manner.  
The contact residues between the two chains are engaged mainly through 
electrostatic interactions. Residues R1985, K1946 and E1950 were found to be 
essential for dimerisation and single mutations of these residues led to inhibition 
of transcription (Nam et al., 2007). The Fragment 12C05 was found at the 
dimerisation interface binding to residue N1984 adjacent to R1985. The 
fragment did not interfere with any of the electrostatic interactions that stabilise 
the two ankyrin-domain chains. However, it is possible to grow the fragment or 
optimise it to engage in interactions with the guanidino group of R1985. This 
could potentially inhibit the dimerisation of the assembled complex; and inhibit 
the gene transcription according to the proposed model. 
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Figure 4.5 Crystal structures of the ankyrin domain both in the isolated structures (PDB 1YYH 
and PDB 2F8Y) and in complex (PDB 2F8X) show conserved head-to-head interactions through 
conserved residues of the ankyrin domain. In A) Crystal contact residues between molecules in 
the asymmetric unit show head-to-head interaction (PDB 1YYH) B) Residue R1985 in one chain 
of one molecule interacts with the  other chain of another molecule in the assymetric unit (PDB 
1YYH). C) Crystal contacts of the ternary complex are involved through the ankyrin domain 
pseudo-twofold symmetry axis of the crystal (PDB 2F8X). D) The head-to-head interaction of the 
ankyrin domain in the ternary complex is involved again through residue R1985. E)Another 
crystal structure of higher resolution of the isolated ankyrin domain (PDB 2F8Y) shows contact 
residues between the two chains of the same molecule. F)Residue R1985 is involved in hydrogen-
bond interactions with  backbone carbonyl groups (PDB 2F8Y).                                                                      
A B
C D
 E F
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Figure 4.6  A) The crystal structure of the ankyrin domain with fragment 9F07 showing weak 
hydrogen-bond interactions with residues E2072, G2073, A2038 and N2039 (ankyrin domain in 
teal and 9F07 in orange) C) The crystal structure of 9F07 at the second site between the two 
ankyrin chains (Chain A in teal and chain B in violet). B) and D) electron density maps 2|Fo-Fc| 
at a contour level at 1σ showing the fragments at the two sites in A) and C) respectively.                             
 
 4.4.4 The second crystal structure 
The second structure was solved at a resolution 2.5 Å and the first repeat was 
again missing due to its unstructured nature. The electron density of the first 50 
residues in chain A and chain B was very poor, making it impossible to model 
any residues. Similarly, the fragment was found binding in two different 
locations (Figure 4.6).   
 The first binding site for fragment 9F07: 
The first site was located between the upper helices of repeats five and six 
(Figure 4.6A). The fragment is bound mainly through weak hydrogen bonds with 
the carbonyl groups of the main chain of the protein (Table 4.4). One methyl 
group of the methoxy side chain forms a weak hydrogen bond with the carbonyl 
A B 
C D 
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group of main chain amide bond of E2072, and the other forms a hydrogen bond 
with the carbonyl group of main-chain amide bond of A2038. The nitrogen atom 
of the dihydroisoquinoline ring of the fragment forms a hydrogen bond with the 
amino side-chain group of N2040. A water molecule mediates the interaction 
between the methyl side chain of the fragment and carbonyl group of main-chain 
of G2073 through weak hydrogen-bonds. The fragment binds at an unusual 
solvent-exposed site that is too shallow and flat to accommodate small molecules 
or even smaller fragments. However, it was possible to fit the fragment to the 
electron density and to derive interactions with the ankyrin domain. The 
electron density corresponding to the fragment at chain B of the ankyrin domain 
was very weak and it was again difficult to place the fragment 
The second binding site for fragment 9F07: 
The second site was found between the two chains. The fragment is involved in 
only one hydrogen bond with H2019 between the NH of the fragment and the 
nitrogen of the imidazole ring of H2019. The fragment appears to be stacked 
between the two chains through hydrophobic interactions. 
 Table 4.4 Summary of the interactions the fragment 9F07 forms 
Type of interaction                    Residue involved                  Distance 
   Weak hydrogen-bond                 E2072                               2.9 Å 
   Weak hydrogen-bond                A2038                               2.6 Å 
   Weak hydrogen-bond                N2039                               3.2 Å 
   Water-mediated interaction      G2073                    2.7 – 2.8 Å 
   Hydrogen-bond*                         H2019                               2.96 Å           
*This interaction is formed at the dimerisation interface. 
                    
 
4.4.4.1 Implication of the fragment 9F07 on complex formation 
The structure of the ankyrin domain was again superposed with the structure of 
ankyrin domain in the complex structure (2F8X). The fragment 9F07 lies at the 
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interface of the ankyrin domain with MAML and CSL. The fragment interacts 
with residue E2072 through its main-chain carbonyl group. This residue is 
involved through its carboxylic side chain with the hydroxyl group of Y381 of 
CSL. The fragment does not interfere directly with this interaction. There is no 
great conformational change induced by the fragment when compared to both 
the ankyrin structure in isolation (core rmsd = 0.564 Å) and in complex (core 
rmsd = 0.636 Å). The ankyrin domain itself does not undergo any change when it 
forms the ternary complex (Nam et al., 2006). However, the flexible carboxylic 
side chain of E2072 residue is displaced by a distance 1.9 Å distance which 
makes it about 3.3 Å further from the –OH of Y381 which would normally form a 
hydrogen bond with and the carbonyl group of E2072 is displaced by a distance 
1.2 Å (Figure 4.7C). These are small conformational changes that may not be 
significant, given that the ankyrin domain does not undergo large 
conformational changes upon complexation. However, further optimisation or 
fragment-growing could provide a starting point to a molecule that potentially 
diminishes this specific interaction.   
4.4.4.2 Implication of the fragment 9F07 on dimerisation 
The fragment was also found at the dimerisation site of the two ankyrin domain 
chains. As previously highlighted, the complex dimer assembly through the 
ankyrin domain could have an important role in the Notch transcriptional 
activity. The fragment 9F07 binds to the same H2019 as fragment 12C05 
through the same nitrogen of the imidazole ring. This suggests that this site is a 
possible target to explore in order to interfere with the transcription process. 
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 4.4.5 The relative position of the two fragments to each other 
The two structures of the ankyrin domain with the two fragments were 
superposed. The positions of the two fragments were found to be at a relatively 
close distance of about 6 Å. One fragment is positioned at the interface with the 
CSL and the other is located at the interface with MAML (Figure 4.8). The 
presence of two fragments at these sites suggests the possibility of linking the 
two fragments or developing a molecule that could target the two interfaces. 
However, it is difficult to link the two fragments and maintain the same 
conformation and geometry. This will be discussed in more detail in chapter 6. 
The two fragments are located at the dimerisation interface and directed in the 
same orientation. These two molecules have different scaffolds and do not share 
any common functional groups though they both form a common hydrogen-bond 
interaction with residue H2019 of the ankyrin domain. The binding of the two 
fragments in this site could be a crystallographic artefact by stacking between 
Figure 4.7 Implications of the binding of fragment 
9F07 for complex formation. A) Residue E2072 of 
ankyrin forms a hydrogen-bond interaction with 
Y381 of CSL (PDB 2F8X) B) Superposing the 
structure of the fragment complex with the complex 
with MAML and CSL, showing the Fragment 9F07 
interacting with the residue 2072 through the 
backbone carbonyl group. C) Displacement of 
carbonyl group of E2072 by a distance 1.2 Å and the 
carboxyl group by a distance 1.9 Å. (Ankyrin in teal, 
MAML in orange, CSL in violet) 
A B 
 C 
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the two chains or a true binding site that could be targeted. This must be 
validated by mutating the residues involved and testing for binding, but this was 
not possible due to time limitation. 
 
 
 
 
  
 
4.5 Conclusions 
Structure-based drug design is a powerful tool in drug discovery and drug 
development. The availability of structures solved by NMR or X-ray 
crystallography facilitates structure-guided drug design. In fact, X-ray 
crystallography has been used as a screening method in fragment-based 
approaches in an automated manner. It is a valid screening method that 
determines the actual binding mode of ligands with very few false positives. 
 
Figure 4.8 Superposing structures of the ankyrin 
domain with the two fragments. A) A surface 
view of the ankyrin domain showing the two 
fragments at a close distance of about 6 Å. B) 
Superposed structures with MAML and CSL 
showing the location of two fragments at the 
interfaces. C) Surface view of the ankyrin 
domain showing the 2 fragments located 
between the two chains. 
A B 
C 
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False positives may arise from artefactual structures that are usually easy to 
distinguish. Although the ankyrin domain was easily crystallised in various 
conditions and in a reproducible fashion, structures of only two different 
fragments were obtained. Different methods and approaches were used for either 
soaking or co-crystallisation that could overcome problems such as solubility or 
low diffusion rates of the small hydrophobic fragments. The failure to obtain 
structures could be attributed to many reasons: incompatibility of the conditions 
of the initial screening step with the crystallisation conditions, fragment binding 
at positions of crystal contacts, weak binding affinities of these fragments or the 
failure to reach the binding equilibrium owing to their poor solubility. 
However, the structures obtained of the two fragments here are the first 
reported examples so far of small molecules that can bind to the ankyrin domain 
of the Notch receptor. There have been speculations about targeting protein-
protein interfaces with small molecules. The two fragments were found to be 
binding at the interfaces of the ternary complex and the dimerisation interface. 
This could provide a starting point to develop inhibitors, though this would seem 
challenging owing to the flat surfaces of these interfaces and lack of adjacent 
significant pockets to grow to. The two fragments lie close to each other, which 
suggests the possibility of linking them together. This poses another challenge to 
maintain the positions and conformations of both fragments.  
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Chapter 5 
 
Kinetic Studies Using Surface Plasmon 
Resonance 
 
  5.1. Introduction 
Surface plasmon resonance (SPR) is an important biophysical method for 
studying bio-molecular interactions, which has the advantage of measuring 
affinities in addition to interesting thermodynamic and kinetic parameters. 
Developing highly sensitive biosensors has attracted many drug discovery groups 
to implement SPR as a high throughput method for screening large compound 
libraries. Now that fragment-based drug discovery is being integrated in many 
drug discovery programs, the availability of SPR as a label-free detection system 
has made it a primary fragment-screening method. SPR is now an established 
method in companies such as the Genetech division of Roche, the Heidelberg-
based Graffinity  and Vernalis 
 
 5.1.1 Surface Plasmon Resonance 
Surface plasmons are coherent oscillations of electrons that can exist at a metal-
dielectric interface as electromagnetic waves. Surface Plasmon Resonance (SPR) 
is the phenomenon of exciting the surface plasmons by light in thin conducting 
films that separate media of different refractive indices. Biosensors have 
implemented this phenomenon to monitor and study the interaction between 
molecules in real time. In Biacore systems, the optical setup is designed so that a 
glass of a sensor chip is covered by a thin layer of gold as a conducting film. 
When the incident light on the reflecting surface exceeds the critical angle a 
condition of total internal reflection takes place. This forms an electric field 
intensity known as evanescent wave field whose amplitude decreases 
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exponentially with the distance from the surface. Varying the angle of incidence 
or the wavelength of the incident light will excite plasmons in the gold film. In 
resonance conditions, absorption of energy through the evanescent wave field 
creates a decrease in intensity of the reflected light known as a SPR minimum or 
SPR angle. The angle and wavelength of SPR minimum are sensitive to changes 
in the refractive index of the medium adjacent to the metal surface. Changes in 
the refractive index can be caused by variations in the solute concentration at 
the surface of the sensor chip. One interacting partner is attached to the surface 
of the sensor chip and the other is passed over the surface. In case of interaction, 
the change of the local refractive index caused by adsorption of interacting 
molecules is monitored as a change in the SPR minimum reflecting the presence 
of molecules as complexes.  
5.1.2 Advantages of Surface Plasmon Resonance 
SPR offers many advantages that make it a primary screening method for some 
targets. An ideal SPR binding experiment consists of two stages. In the first 
stage, kon, the association rate constant of the ligand and receptor, can be 
measured. In the second dissociating stage, the sample is rinsed by the running 
buffer and koff, the dissociation rate constant of the receptor-ligand complex to 
free ligand and receptor molecules, is calculated. The binding constant Kd can 
then be computed (Kd= koff / kon).  
The fact that SPR consumes only a few micrograms makes it suitable for 
proteins that have very low expression yields or are expensive to produce. 
Another advantage is that it does not require labelling of the compounds, so 
facilitating its use for high-throughput screening. Furthermore, it is possible to 
use organic solvents such as DMSO for poorly soluble compounds. Monitoring the 
stability of the ligand protein by observing the baseline behaviour is possible 
using biosensors. This is very important in the drug optimisation process, as it 
gives information about the drug residence time, which can reflect the 
pharmacological effect and target selectivity (Copeland et al., 2006). Target 
selectivity can be estimated by comparing the half-life times for both targets and 
non-targets, which are often referred to as off-targets (Copeland et al., 2006).  
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This highly sensitive technique can measure Kd values ranging from 1mM and 
1pM and in real-time, so allowing characterisation of kinetic events. 
 
5.1.3 Limitations of Surface Plasmon Resonance 
Surface Plasmon resonance is still restricted in its use for high-throughput 
screening by several factors that need to be addressed. The coupling of the target 
protein can occur at the binding site, so interfering with recognition of potential 
ligands. This can be avoided by using different coupling and immobilisation 
methods; thiol coupling for instance might help to immobilise the proteins in a 
defined orientation with less coupling sites than amine coupling, thus allowing 
for more selectivity. The conditions of the assay can affect the behaviour of the 
binding of ligands. The choice of buffer, pH, and temperature may either improve 
or worsen the binding sensorgram profiles. These will require initial 
optimisation before carrying out the binding studies. 
Regeneration will depend on the nature of interaction of the ligands with the 
protein. Interactions with small molecules such as fragments, which likely 
involve ionic or hydrogen-bond interactions, can be reversed using NaCl as a 
regenerating solution.  On the other hand, some ligands may interact with the 
protein irreversibly through covalent bonding, which will require more drastic 
conditions for regeneration. These conditions may destroy the protein activity 
and impair the performance of the assay.  
In highly sensitive biosensors, other components of the buffer could interfere 
with the data interpretation. This can lead to masking of the actual binding 
kinetic data or providing false measurements. Such molecules could be the buffer 
itself, for example HEPES, or molecules such as DMSO in the ligand sample 
solutions and running buffer, which are both small molecules that bind to many 
proteins and may compete at the binding site. These problems have been 
overcome either by using a different buffer such as phosphate or by applying the 
solvent correction method to exclude the effect of DMSO.  
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The distinction between valid and false-positive hits is an important part of the 
screening process. False positives must be identified and discarded from any 
initial medicinal chemistry programs. They can be detected by inspecting their 
SPR behaviour over a range of concentrations. A classification system has been 
developed to help in identifying these promiscuous inhibitors (Giannetti et al., 
2008). The first group consists of compounds that bind with a stoichiometry five 
times higher than expected; these are known as superstoichiometric compounds 
and are eliminated from further follow up (Giannetti et al., 2008). The second 
group encompasses compounds that have a stoichiometry lying between 1:1 and 
5:1 (protein: compound); these are labelled as non-stoichiometric compounds and 
should be tested in other assays (Giannetti et al., 2008). The third group, which 
includes concentration-dependant aggregators, consists of compounds that tend 
to aggregate at higher concentrations and bind non-specifically to the target 
protein (Giannetti et al., 2008). These compounds are eliminated from the 
screen. 
In this chapter I describe the characterisation of a selected set of fragments 
identified in the primary screen (Chapter 3), the optimisation of the fragment 
12C05 and the study of indirubin-3'-monoxime binding to the ankyrin domain.  
 
5.2 Characterisation of fragments and small molecules 
5.2.1 Characterisation of some of the fragment hits 
A fluorescent-based thermal shift assay has been used to identify initial hits in a 
primary screen (Chapter 3). The binding constants of the fragment hits detected 
were measured using the Biacore T100 system which implements the surface 
plasmon resonance phenomenon.  
 5.2.1.1 Materials and methods 
        i) Immobilisation 
            a) Buffer pH and protein pre-concentration 
91 
 
An important step prior to protein immobilisation is electrostatic pre-
concentration in a dextran matrix. A sensor chip CM5 was used where the 
carboxymethylated dextran on the sensor chip surface acquires a negative charge 
at a pH above 3.5. The optimum conditions required for the ankyrin protein to 
become positively-charge were scanned using pH-scouting experiment. The 
ankyrin protein solutions were prepared in different coupling buffers to be tested 
at different pH values; acetate pH 4, acetate pH 4.5, acetate pH 5 and pH 5.5 at 
a final concentration of 1 µM. The running buffer used was HBS which is 
commercially available from Biacore (10 mM HEPES pH 7.4, 150 mM NaCl, 0.05 
% P20) at a temperature 25 °C. 
               b) Immobilisation procedures 
After choosing the optimum buffer solution for the protein, the surface of the 
sensor chip was activated using a mixture of 0.4 M EDC (1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide) and 0.1 M NHS (N-hydroxysuccinmide). 
The ankyrin domain was prepared in acetate buffer pH 4 to reach a final 
concentration 1 µM. It was immobilised by injecting at a flow rate 10 µl/min until 
it reached the target RU. This was followed by deactivating the remaining active 
groups on the surface by injecting 1M ethanol-amine-HCL pH 8.5. 
 
The amount of protein to immobilise was calculated using the following formula: 
Immobilised protein(RU)
ligand binding capacity(RU) =
 Protein MW
ligand MW  
                       
          
   ii)  Kinetic analysis of fragments 
Serial dilutions of the fragment solutions were prepared either in buffer HBS (10 
mM HEPES pH 7.4, 150 mM NaCl and 0.05 % P20) or in PBS buffer ( 10 mM 
phosphate buffer pH, 150 mM NaCl and 0.05 % tween 20) depending on the 
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solubility of the fragments. Some fragments were dissolved in 5% DMSO and the 
running buffers were also prepared in 5% DMSO. In these cases, solvent 
correction working solutions were designed by preparing a series of aliquots 
using PBS or HBS containing 4.5% and 5.8% DMSO according to the following 
table: 
Table 5.1 Preparing the aliquots for solvent correction solutions 
Buffer\Vial 1 2 3 4 5 6 7 8 
4.5%  200 400 600 800 1000 1200 1400 
5.8 % 1400 1200 1000 800 600 400 200  
Total 
volume 
1400 1400 1400 1400 1400 1400 1400 1400 
 
The fragment solutions were injected onto the surface of the chip at a flow rate 
30 µl/min, contact time was 60 seconds and dissociation time was 60 seconds.  
The sensorgrams were analysed using the Biacore T100 evaluation software. 
Solvent correction was applied in cases where DMSO was used.  
 
5.2.1.2 Results and discussion 
Immobilisation was carried out using the amine coupling method which is the 
most common approach used. In this method the carboxylic group of the 
activated surface of the sensor chip is covalently linked with free amino groups. 
Although these should not be at or near the active or binding site, in the case of 
the ankyrin domain there is no structural information about where the 
fragments might bind. The ankyrin domain protein was prepared in acetate 
buffer pH 4 to pre-concentrate the protein to the surface of the chip. In this 
approach the immobilisation target depends on the purpose of the analysis; lower 
levels of immobilisation are usually recommended for kinetic measurements in 
order to reduce the effects of mass transport of the ligand to the surface. 
However, kinetic analysis of low molecular weight ligands requires higher level 
of immobilisation as the SPR response depends on the mass. The immobilisation 
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target according to the formula (see Materials and Methods) was calculated to be 
about 7647 RU. The immobilisation level only reached about 4400 RU which was 
still high enough to carry out kinetic studies. 
Biacore has been used to characterise the binding of some fragments that have 
been picked from the preliminary screen. Some fragments were not readily 
available for subsequent kinetic analysis. The solubility of the fragments varied, 
some being soluble in the running buffer whilst others required 5% DMSO to 
improve the solubility. The common buffer which was used as a running buffer in 
kinetic and binding screening was HEPES buffer which may interfere with 
binding (see comments in Introduction). Other buffers were investigated; 
phosphate buffer was considered the buffer of choice in fragment analysis. 
However, the HEPES buffer, which is a sulfonic acid derivative, was shown not 
to bind in the initial screening of the fragment library and in the buffer screen. 
This allowed the use of HEPES in the running buffer in cases where it improved 
the solubility of the fragment without concern about possible non-specific or 
interfering binding. In addition, the buffer was always run as a control in the 
kinetic analysis experiments and it was subtracted from the fragment run 
indicating that any response observed would be solely a result of binding of the 
fragment. 
Two methods are used for analysis of the sensorgrams to measure the binding 
constant. The first fits the experimental data to a mathematical model. This 
often requires knowledge of the interactions, for example about multiple 
interaction sites or conformational changes. The fitting procedure includes an 
iterative process to find the best fit for an equation that can describe the 
interaction. In kinetic assays, at least five different concentrations are necessary 
to extract kinetic parameters.  Parameters in the fitting equation are assigned 
either locally or globally. Local parameters are usually concentration and bulk 
refractive index contribution which are assigned independently for each curve. 
Global parameters are assigned for the whole dataset; this provides more robust 
values for the rate constants. Local parameters can be used for determining rate 
constants in cases where the protein activity is variable in different cycles such 
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as a change of capture level in capture assays. The simplest binding model is a 
1:1 binding interaction: 
A+B=AB 
 
The second method is based on affinity determination where the Kd is measured 
as the ligand concentration that gives a response corresponding to half Rmax.  
Fragments are weakly binding molecules that usually have very fast on- and off-
rates. The typical sensorgram for fragments is characterised by a square-shaped 
plot. Although the various kinetic parameters cannot be derived from these 
sensorgrams, the dissociation constant can still be measured by the steady state 
method where steady state binding levels (Req) values are plotted against sample 
concentration (C). The Kd can be computed from the following equation: 
Req =  ୈ୫ୟ୶୏ୢାେ +  RI 
  RI is the refractive index contribution 
It should be pointed out that these weakly binding fragments might bind in the 
millimolar range. The concentration range of the samples prepared for analysis 
should include concentrations higher and lower than the expected Kd. The 
fragments are quite hydrophobic molecules with limited solubility and they tend 
to aggregate at higher concentrations. To avoid the aggregation of the 
compounds at the surface of the chip, the samples are usually centrifuged down 
to eliminate the effect of binding of aggregates. However, the concentration of 
samples is then less than it estimated and the computed Kd value would be 
underestimated. It is therefore advisable to measure the new concentrations of 
the samples after centrifugation for a more accurate calculation. However, this 
seemed difficult with the small-volume samples and the lack of an adequate 
method to measure concentrations of small volumes. The calculated Kd then 
would be a rough estimate of the binding affinities but could still be used to 
establish SAR tables in some cases. 
95 
 
Specificity has often been a concern when the binding site is uncertain. As a 
consequence, on screening using biosensors, a counter-protein is usually used 
that is either the same target but the active site is blocked, or another protein 
that is known for not binding to these molecules. However, in the early stages of 
drug discovery, specificity and selectivity of fragments is generally of less 
importance than in more advanced stages. The aim of the first hit-identification 
phase is to identify the main chemical moieties that bind to the protein and to 
measure their potency. This was the purpose of the experiments described here. 
Some fragments did not show any binding despite being identified as positive 
hits in screening using the thermal shift method (Chapter 3). This may be a 
consequence of one or more factors. First these fragment hits could have been 
false-positives although some of them were analogues of confirmed hits and it 
would have been expected that they would give a binding response. Secondly, the 
immobilisation of the ankyrin domain may have been unfavourable for the 
fragment binding. Thirdly, the solubility of the fragments may be too low even 
after solubilising in 5%DMSO. Fourthly, the compatibility of the initial screening 
conditions with the running buffer conditions could also introduce a source of 
variation between the results from screening and kinetic analysis. Possible 
variations include different buffers or pH values that could alter the ionisation or 
protonation states of the fragments. Very small differences in pH can be very 
critical in determining the ionisation state that is favourable for binding; and 
this depends on the ionisation constants of the fragments as well. In the 
experiments described here the screening of the fragment library was carried out 
at a pH 8.5 while the kinetic analysis was carried out pH 7.4.  
Ideally, the fragments should all be tested in the same conditions. However, the 
conditions for each fragment in these experiments were individually optimised to 
improve solubility; this included changing the buffer, the pH and sometimes the 
temperature. This could introduce errors in comparing Kd values or other kinetic 
parameters, but on balance was considered worth doing. Regeneration of the 
surface using 1M NaCl was sufficient to restore the baseline, especially for those 
fragments with fast off-rates.  
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Fragment 12C05 was fitted to a 1:1 kinetic model. Although it was shown to bind 
at two different sites in the crystal structure, the sensorgram seemed to fit well 
in a 1:1 model. In addition, the bivalent kinetic model describes the binding of 
two molecules to two equivalent binding sites on the protein. It has been 
demonstrated crystallographically that the fragment 12C05 binds at the upper 
helices between repeats six and seven in one position. The second site observed 
in the crystals is between the two ankyrin chains. The fragment is likely binding 
to individual ankyrin molecules only very weakly and is not observed in solution.  
 
The affinities of three other compounds analogous to 12C05 were measured. 
From these experiments it was clear that differences in side chains of the phenyl 
ring caused variations in affinity. Replacing the methyl amino group with an 
amino group improved the affinity from 7.80 mM to 1.58 mM while replacing it 
with a hydroxyl methyl group decreased the affinity to 10.45 mM. The highest 
affinity was observed when the pyrrolidine ring was replaced with a piperdinyl 
ring showing an affinity of 0.968 mM.  
The interactions of fragment12C05 with the ankyrin domain were elucidated by 
the protein-fragment crystal structure. The fragment is stabilised by many 
interactions including a π-π aromatic interaction with residue Y2075 and a salt 
bridge with D2109 with the nitrogen atom of the pyrollidine ring. The pKa 
values of the nitrogen atom of the pyrollidine and piperdine ring in case of 14B04 
were calculated using an online calculator http://sparc.chem.uga.edu/sparc/. 
These variations did not cause any dramatic changes in the pKa values. Under 
the running buffer and sample buffer conditions, which are at a pH 7.4, the 
nitrogen atoms are positively charged. This means that the salt bridge with 
D2109 is unaffected by changes in the phenyl side chain. Instead, the difference 
in affinities is likely caused by a change in the strength of the π-π aromatic 
interaction by the direct effect of these substituents on the phenyl ring. In case of 
14B04, the replacement of the pyrollidine ring with a piperdine ring could favour 
the positioning of the nitrogen atom to form a better salt bridge. The five-
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membered pyrroldine ring adopts a puckered conformation whereas the six-
membered piperdine ring is found in a chair conformation. 
Fragment 9F07 was identified in the first screen and detected in the crystal 
structure as well. It showed a binding response in the Biacore experiments but 
failed to reach a saturation level with increasing concentrations. This could 
indicate that it is binding very weakly and to reach saturation would require 
higher concentrations at which the fragment would start to aggregate. 
 
 
Table 5.2 A table list of the fragments tested and their corresponding kinetic parameters 
Fragment Binding Kd (mM) Kon (M-1s-1) Koff (s-1) 
12C05 
 
Binding 7.876 ± 1.05 
 
2.356±0.22 0.018±0.0007 
 
12D05 Binding 1.586 ± 0.15 
 
12.43± 0.90 
 
0.019±0.003 
12B05 Binding 10.45 ±1.668 - - 
14B04 Binding       0.968 ± 0.237 
 
- - 
14H04 Binding 1.90 ± 0.78 
 
- - 
1605 Binding 0.3908 - - 
12E03 No binding - - - 
12H05 No binding - - - 
12E06 No binding - - - 
9A03 No binding - - - 
10H10 No binding - - - 
13A09 No binding - - - 
 
 
 
 
        A                                                                                            B 
Kd=7.87 mM                                       Kd=  1.58 mM             
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       C                                                                                              D      
    
        E                                                                                                F 
   
 
Figure 5.1 Sensorgrams of fragments shown to bind using thermal shift and estimated Kd 
values. In A) the fragment 12C05 and in B) fragment 12D05, the sensorgrams were fitted to a 1:1 
model and kinetic parameters were derived. In C) fragment 14B04 , D)fragment 12B05, 
E)fragment 14H04 and F)fragment 1605, Kd  values were only measured by steady state affinity. 
 
 
 
 
Table 5.3 List  Kd  and pKa values of fragments 12C5 and its analogous 
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Fragment                      Kd                                    pKa 
12C05         7.876 ± 1.05 mM           9.36 
12D5              1.586 ± 0.1 mM             9.43 
14B4        0.968 ± 0.237 mM          9.36 
12B5        10.45 ±1.668 mM            9.43 
 
5.2.2. Characterisation of optimised fragment 
Fragment 12C05 has been validated as a positive hit using three different 
biophysical techniques: fluorescent based-thermal shift assay, SPR and X-ray 
crystallography. The fragment has been optimised on the basis of the 
information gathered from these methods. The crystal structure suggested that 
the fragment was involved in a number of interactions. These interactions 
include a face-to-face π-π aromatic interaction, weak hydrogen bonds and a salt 
bridge. Optimisation of the fragment aimed at finding the heterocyclic ring that 
would bind with highest affinity and enhance the interaction (Figure 5.2).  
 
5.2.2.1 Materials and methods 
The Biacore run was set up as described earlier (see section 5.2.1.1). Compounds 
A, B and C were synthesised by Dr Hamid Nasiri (Department of Chemistry, 
University of Cambridge). The concentration series for the compounds were 
prepared as following: 
For compound A: 37.5, 18.75, 9.38, 4.69, 2.34, 1.17, 0.58 mM. 
For compound B: 18.75, 9.38, 4.69, 2.34, 1.17, 0.58, 0.29 mM. 
For compound C: 37.5, 18.75, 9.38, 4.69, 2.34, 1.17, 0.58 mM. 
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The sensorgrams were analysed using the Biacore T100 evaluation software. 
Solvent correction was applied in cases where DMSO was used. 
 
                                        
 
                                                                                                  
                                                                              
 
 
Figure 5.2 A summary of the optimisation approaches designed to optimise the fragment 12C05. 
The chemical moieties in dashed red circles were identified as pharmacophoric points involved in 
important interactions with ankyrin amino acid residues. These moieties were replaced by other 
rings or substitutions that were thought likely to enhance these interactions 
  
5.2.2.2 Results and discussion 
The π-π aromatic interaction should be improved by enhancing the stacking; this 
might be achieved by increasing the electron density at the phenyl ring. 
Replacing the phenyl ring by a naphthalene ring would increase the 
delocalisation of the electrons through the conjugated system.  
The affinity of the compound A was measured using SPR by the steady state 
method. It bound to the ankyrin domain with a Kd  21.95 mM, an approximately 
three-fold decrease in affinity compared to the original fragment. This could 
indicate that the naphthalene ring is not favourable for binding as expected. The 
resonance structure of the naphthalene ring could have affected the basicity of 
the nitrogen atom of the pyrroline ring. The nitrogen atom was involved in a salt 
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bridge interaction with the acidic carbonyl group of the aspartate residue 
Asp2109 of the ankyrin domain.  
 
         
A 
   
B 
 
 
Figure 5.3 The effect of replacing a phenyl ring with a naphthalene ring and removing the 
methyl amino side chain on the affinity. In A) the sensorgram of the compound showing fast on- 
and off-rates, and in B) a steady state affinity measurement of a Kd value of about 21 mM 
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Figure 5.4 Sensorgram showing the effect of replacing the pyrroline ring with a morpholine ring. 
Aggregation is observed at higher concentration (18.75 mM) 
 
 
 
 
Figure 5.5 Replacing the methyl amino side chain by a methyl pyrroline inhibited the binding 
and aggregattion was observed in sensorgram of two high concentration values (37.5 and 18.75 
mM) 
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Figure 5.6 Adding a methoxy group did not have a significant affect on the affinity which was 
measured by steady-state which showed that the new molecule was binding at a Kd  15.23. 
 
 
The pyrroline ring was replaced by a morpholine group and the phenyl ring by a 
naphthalene ring in compound B. These changes were made in order to explore 
different ring systems in order to identify the ring with highest affinity. The 
sensorgram showed binding as the RU values increased with increasing 
concentration, but this could be a false positive as a result of aggregation. The Kd 
values were not calculated as compound B starts to aggregate and precipitate at 
higher concentration as seen at 18.75 mM. The Kd values are likely to be between 
9 and 30 mM.  This result suggested that the morpholine ring is not favourable 
for binding as it has been confirmed by fluorescent-based thermal shift assay 
(Chapter 3). 
The methyl amino side chain was replaced with a methyl pyrollinyl group in 
compound C. The larger group was targeted to bind to the small adjacent pocket 
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in an attempt to grow the fragment 12C05. It did not show any binding response 
at lower concentrations but showed a jump in the signal at higher concentrations 
indicating aggregation. This compound falls in the category of concentration-
dependant aggregators that are normally eliminated in the screen. However, the 
compound might be improved by replacing the side chain with an ethyl-pyrollinyl 
group instead. 
These results showed that the fragment 12C05 is the best scaffold binding to the 
ankyrin protein despite its weak affinity. Optimising this fragment has proven to 
be difficult, probably due to the many interactions through which it is involved 
with ankyrin domain residues. These interactions seem to be finely balanced so 
that optimising one interaction may adversely affect the rest of the interactions. 
5.2.3 Characterisation of Indirubin-3'-monoxime 
Indirubin is an active component that can be found in the Chinese herb Danggui 
Longhui Wan. It has been traditionally used for its therapeutic benefits in 
treating chronic diseases (Eisenbrand et al., 2004; Xiao et al., 2002). Indirubin 
and its derivatives have been identified as inhibitors for a number of targets 
(Adachi et al., 2001; Bian et al., 2003; Bertrand et al., 2003; Nam et al., 2005). 
They have recently been found to inhibit the Notch1 signalling pathway as well. 
The main mechanism of inhibition was through inhibiting the function of 
glycogen synthase-3β (GSK-3β). GSK-3β regulates the Notch1 signalling pathway 
by controlling the proteosomal degradation of Notch intracellular domain 
through its direct phosphorylation. Indirubin derivatives caused different 
inhibition activities on the Notch signalling (Foltz et al., 2002; Epinosa et al., 
2003). In addition, indirubin-3'-monoxime was found to inhibit the interaction 
between Notch intracellular domain and RBP-Jk (Lee et al., 2008). This 
suggested that the indirubin-3'-monoxime could bind with either of the two 
proteins so I tested whether it binds to the ankyrin domain using the SPR 
technique. 
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5.2.3.1 Results and discussion 
Indirubin-3'-monoxime is the only small compound that has been reported so far 
to have any inhibitory effect on the physical interaction of the Notch1 
intracellular domain and RBP-Jk. This was demonstrated by co-
immunoprecipitation assays, showing that indirubin-3'-monoxime could interact 
with either protein and prevent the interaction. Indirubin-3'-monoxime is a small 
molecule of molecular weight of 277.28 Da. Fragmenting indirubin-3'-monoxime 
through the double bond would result in indole derivatives, which are similar to 
the chemical moieties that were observed in primary fragment screening. It was 
tested against the ankyrin domain but showed no binding at any concentration 
that experimentally possible to test. This suggested that the indirubin-3'-
monoxime does not bind to the ankyrin domain. However, it could bind to other 
regions of the Notch intracellular domain or exhibit its inhibitory action by 
binding to the RBP-Jk instead. This could be because indirubin-3'-monoxime is a 
very planar molecule with limited flexibility. There is a tendency for protein-
protein inhibitors to be large, rigid and hydrophobic (Higueruelo et al., 2009). 
They also possess a higher ring count than drugs and ligands found in the PDB. 
Indirubin-3'-monoxime consists of four aromatic rings, if each indole ring is 
considered as two rings. This affects the solubility of the molecule as well as 
other physical properties such as logP. 
 
  
Indirubin-3'-monoxime 
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Figure 5.7 Sensorgrams of indirubin-3'-monoxime at various concentrations showing no binding 
responses to the ankyrin domain. 
 
The concentration of indirubin-3'-monoxime that caused the inhibition of the 
protein-protein interaction was not stated (Lee et al., 2008). The ankyrin domain 
could be an off-target that binds with less specificity at a higher concentration 
than used here, but indirubin-3'-monoxime was insoluble at higher 
concentrations in the conditions used in this kinetic analysis. 
5.3 Conclusions 
Measuring binding affinities for molecules is an important step in the drug 
discovery process. In early screening stages, its importance lies in prioritising 
small molecule hits for proceeding from hit-to-lead. The challenge at this stage is 
to find a sensitive technique that can help in measuring weakly-binding 
affinities. The development of sensitive biosensors has made it possible to 
quantify and analyse these molecules. In fact, it has been used as a primary 
high-throughput screening for fragments. However, interpretation of the data 
retrieved may not be straightforward in some cases and requires additional 
information to explain the binding behaviour observed in different sensorgrams. 
Another hurdle to overcome in analysing small fragments is their poor water 
solubility; the use of organic solvents as DMSO can help to improve the solubility 
in some cases, but there is always a risk of aggregation that could lead to false-
positive results. 
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The binding affinities measured combined with other structural information can 
help in optimising and developing fragments in a structure-based approach. 
However, fragment 12C05 was the only fragment that was characterised both 
structurally and kinetically. Nevertheless, the information helped in designing 
some compounds I thought might improve the binding affinity. Unfortunately, 
none of the proposed compounds has significantly changed affinities, although 
small changes were observed that help in understanding the interactions. 
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Chapter 6 
 
Computational Methods for Fragment 
Elaboration 
 
 
6.1 Introduction 
Computational approaches have proved useful tools to complement experimental 
approaches in the drug discovery process. Computational methods have been 
integrated at different stages starting with hit identification using virtual 
screening, on to hit-to-lead optimisation and through to improving 
pharmaceutical and physical properties. Virtual screening selects molecules from 
larger libraries by docking. De novo design on the other hand generates new 
molecules within the boundaries of a binding pocket.  A wide variety of programs 
have been developed for structure-based drug design (Table 6.1), most of which 
implement techniques to explore the translational, rotational and conformational 
spaces of small molecules in the site of interest. They also employ scoring 
functions to estimate the free energy of binding for a pose, to predict the binding 
mode and to rank molecules in large libraries. 
Other important computational analysis tools in the drug design process include 
pharmacophoric screening to identify the three-dimensional geometric 
arrangement of the essential features in the binding site. This suggests applying 
pharmacophoric descriptors as constraints for virtual screening and as 
descriptors for library design. 
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Table 6.1 A list of selected programs for docking and de novo design  
Docking 
GOLD 
 
Autodock               
 
 
 
DOCK 
 
 
De novo design 
 
SPROUT 
 
 
SPLICE 
 
 
LEGEND 
 
Genetic Algorithm, empirical scoring 
function 
Simulated annealing, Genetic Algorithm, 
AMBER scoring function 
 
Combinatorial docking, multiconformer 
rigid-body docking, AMBER scoring 
 
 
 
 
Fragment-based, sequential growth and 
combinatorial search 
 
Recombination of ligands from database 
search 
 
Atom-based and stochastic search 
 
 
(Jones et al., 1995) 
(Morris et al, 1998) 
 
(Ewing et al., (2001) 
 
 
 
(Gillet et al., 1993) 
 
(Ho & Marshall, 1993) 
 
(Itai & Nishibata, 1991) 
 
 
6.2 De novo design of molecules using SPROUT 
Creating new compounds in de novo drug design programs with no chemical 
restrictions can generate too many suggestions to deal with in limited computer 
time. Nevertheless, de novo design remains an important idea-generating tool in 
early stages of a drug discovery program. Synthetic tractability of the generated 
molecules could be solved by restricting the chemical search space to compounds 
that can be easily synthesised through known chemical reactions. De novo 
programs that employ various techniques have been developed (Table 6.1). 
SPROUT produces molecules through fragment-based sequential growth and 
combinatorial search (Gillett et al., 2004).  One approach is to grow the ligand by 
sequential adding of fragments to a specified point in the binding site. Another 
involves fragment placement and linking by placing fragments and docking them 
to the energetically favourable pose and then connecting them with spacer 
linkers.  
 
 
110 
 
 6.2.1 Fragment growing and fragment linking 
SPROUT, a useful de novo structure building software, generates structures 
according to set specifications, including ring sizes, numbers of rings, rotatable 
bonds and other parameters selected by the user from a built library template or 
from a library designed beforehand. SPROUT represents a modularised system 
that facilitates structure-based drug design at various stages. This can be 
achieved through five modules that run consecutively, starting from binding-
pocket identification and followed by target site identification. This detects 
hydrogen bonding and hydrophobic regions in the binding pocket that can be 
useful for positioning potential ligand atoms. Functional groups are then docked 
to selected positions and linked together by generating skeletons that comply to 
preset steric constraints. The results generated can then be clustered and scored 
for evaluation. SPROUT can also be used in hit optimisation in order to design 
molecules by linking two fragments at adjacent sites.  
In the following sections, I describe the design of compounds using SPROUT by 
linking the two fragments 9F07 and 12C05 that were characterised 
crystallographically. SPROUT was also used to design larger compounds of 
12C05 by growing the fragment to adjacent pockets. 
 
6.2.2 Materials and methods 
SPROUT is part of a three-package product line that has been developed at the 
University of Leeds. SPROUT version 6.2 was employed here for de novo drug 
design. A license for using this software to implement it in the fragment 
elaboration process was kindly provided by Professor Peter Johnson, University 
of Leeds. 
 i)  Protein Template 
The protein-ligand structure of the ankyrin domain bound with fragment 12C05 
was used here as a protein template. The protein was prepared by adding 
hydrogen atoms and assigning the protonation states according to the 
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surrounding environment. The amide groups of asparagines and glutamines 
were flipped according to the most likely hydrogen-bond network. Histidine 
residues were visually inspected and tautomeric states were assigned to allow for 
the most favourable interactions. This was performed using the software 
SYBYL® 8.0.  
  
ii) SPROUT modules 
The SPROUT software is an interactive system in which the modules are set as 
following: 
a) CANGAROO module: The acronym stands for Cleft ANalysis by Geometry 
based Algorithm Regardless Of the Orientation. In this module the protein-
ligand template PDB file was used as an input file. The protein-fragment 
structure is divided into three sets: protein, water molecules and fragment.  
        In fragment growing: the fragment 12C05 is selected and defined as a cavity                      
(ligand) file. The receptor file was defined by cutting a section around the cavity 
rather than using the whole protein structure. A section of a radius 15 Å around 
the fragment was selected and identified as the receptor file. 
In fragment linking: The same protein-fragment structure was used and the 
fragment 9F07 was imported. Both fragments 12C05 and 9F07 were selected 
and defined as the cavity (ligand) file. The receptor file was selected by 
defining a cleft 10 Å around the selected cavity. 
b) HIPPO module: The acronym stands for Hydrogen Bonding Interaction Site 
Prediction as Positions with Orientations. In this module, the possible 
binding targets within the selected receptor were explored and defined.  
Hydrogen bond donors and acceptors were identified and hydrophobic regions 
and surfaces are investigated. 
 In fragment growing: a spherical target site with a radius of 0.5 Å was 
created at both site1 and site2 (Figure 6.2).   
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In fragment linking: The two fragments; 12C05 and 9F07 were imported and 
the points of attachment for linking the two fragments were selected as 
vertices.  
c) ELEFANT module: The acronym stands for ELEction of Functional groups 
and ANchoring them to Target sites. Functional groups from a template 
library were selected as docking start templates. The selected groups are then 
docked and positioned to satisfy the selected site.  
In fragment growing: The docking start templates for both site1 and site2 
included five-membered rings, six-membered rings, methyl group and 
derivatives, amino groups and derivatives, guanidinium group and sulfonyl 
group. 
In fragment linking: No flexibility was inferred on either fragment so as to 
maintain their conformations. 
SPIDER module: This acronym stands for Structure Production with 
Interactive DEsign of Results. The docking start templates are connected 
with selected spacers in this module. Spacer templates are defined from a 
spacer template library. A large number of spacers was selected, including 
flexible saturated and unsaturated alkyl chains and derivatives, three-
membered, four-membered rings, five-membered rings and derivatives.  
In fragment growing: This module was run separately for site1 and site2. 
In fragment linking: The same spacer templates were selected. 
 
d) ALLIGATOR module: This acronym stands for ALgorithms for LIGAnd 
Testing and Ordering of Results. This is the final module where the results 
are visualised, scored according to a built-in scoring scheme and ranked. The 
first one hundred highest-ranking were selected as a set and imported as a 
SDF and PDB file for further analysis. 
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6.2.3 Results and Discussion 
6.2.3.1 Fragment linking  
 
Linking two fragments that bind at proximal sites is not as straightforward as it 
may appear. There are many factors to consider while attempting to link two 
molecules. First, the protein conformation that binds one fragment may differ 
from the one that binds the other. This could be useful in cases of positive 
allosteric cooperativity, where the binding of one fragment causes a favourable 
conformation change allowing the binding of another fragment in a distant site. 
It could even create a new binding pocket that may be a new binding site. It is 
also preferable in cases of configurational cooperativity, where the number of 
unproductive configurations of the protein is reduced (Whitty, 2008). Fragment 
linking could actually be more significant if the two fragments or molecules were 
observed to bind in the same protein structure so that variations in conformation 
are avoided.  
The next decision concerns the choice of the size, orientation and chemistry of 
the linker, which should not be too short to cover the distance and not too long; 
and it should maintain the orientation and conformation of both fragments to 
allow proper binding. The flexibility of the linker is also important to consider. 
Rigid linkers have the advantage of minimal conformational entropy, although 
they restrict the conformation of the linked molecule. This could increase the 
chances of unfavourable interactions with the protein or cause improper binding 
due to incorrect orientation. On the other hand, flexible linkers can adopt 
different conformations without causing steric strain, allowing for sampling of 
conformational space.  
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Nevertheless, they gave an idea of the linker length and the appropriate 
chemistry that could be considered. 
 
6.2.3.2 Fragment growing using SPROUT 
The fragment 12C05 is located at a very shallow surface that is devoid of any 
distinct pockets. This makes it difficult to elaborate and grow the fragment to 
give molecules of higher affinity and good ligand efficiency. There are two 
potential sites that the fragment could grow to (Figure 6.2). The first is a small 
pocket lined with polar and hydrophobic residues: D2109, I2110, R2112 and 
L2113. The fragment 12C05, identified in the preliminary screening of the 
fragment library, was used as the starting point for adding new groups and 
docking the new compounds to the binding site. The new groups were added from 
a template library provided in the software. The distance from the methyl amino 
side chain of the fragment to site 1 is about 8 Å. The new groups selected for 
docking in this site were small groups such as methyl or amino groups or 5 
membered-rings. This appeared to be more suitable for the small pocket rather 
than larger groups. Simple alkyl chains were selected as linkers. These alkyl 
chains could be involved in lipophilic interactions with the hydrophobic residues. 
These interactions are essential in many protein-ligand stabilising interactions 
which arise mainly by the replacement and release of ordered water molecules 
The fragment molecule was maintained in the same conformation by applying 
constraints to keep the same pharmacophoric points that preserve the primary 
interactions. The skeletons formed were then scored according to the interactions 
they formed using a SPROUT scoring scheme, the higher the score the more 
favourable the structure. The compounds that scored higher were compounds of 
aliphatic branched side chains while compounds containing cyclic groups scored 
less (Figure 6.3). 
 There is a second potential site that could be targeted for fragment growing. It is 
a shallow and flat surface where it would be difficult to introduce groups that 
form contacts with the protein residues. This site (site 2) is lined with residues 
116 
 
E2072, G2073, V2039, N2040, and E2076. This site lies proximal to the interface 
of the ankyrin domain with MAML, although there are no residues that directly 
interact. This could be useful for an enhanced inhibitory role rather than 
improving the binding affinity. Again, the fragment 12C05 was used as the 
starting point and groups were added to position 4 of the benzene ring of the 
fragment 12C05. The groups that were selected from the template library were 
more flexible chains containing functional groups such as sulfonamides and 
guandinium groups. The choice of these chains should be more favourable in the 
case of flat protein surfaces rather than cyclic side chains. The compounds that 
were ranked top contained branched chains (Figure 6.4). 
Certain limitations and caveats should be considered on assessing the generated 
molecules. The protein residues remain constrained and rigid throughout the 
docking, and only the ligands are allowed limited flexibility. Even here the 
fragment was remained constrained to maintain the original interactions and 
the new groups only were allowed flexibility. The suggested molecules are 
selected with respect to their availability or ease of synthesis. However, the 
approach remains complementary to other computational tools in drug design. 
The fragment 9F07 was also characterised crystallographically suggesting that it 
could be optimised using computational methods. However, this appeared to be 
challenging for two reasons. First, it binds very weakly with an affinity greater 
than 40 mM which would not make it the best candidate hit to start with. 
Secondly, the fragment was found to bind at a very shallow surface with no 
adjacent pockets or contacts that could provide an anchor to grow the fragment 
to. 
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6.3 Virtual screening 
 
The docking process consists of three main steps: posing, scoring, and ranking. 
The poses are possible docking solutions for the ligand on the surface of the 
receptor. The process of scoring estimates how well the ligand fits the docking 
site and ranking uses the scoring functions to order the poses according to their 
likelihood of being the correct solution. Three main types of scoring function are 
used: force-field-based, empirical and knowledge-based.   
(i) Force-field-based scoring functions depend on estimating the binding 
energies using molecular mechanics force fields. The internal energy of 
the protein is not calculated as only one protein conformation is used, and 
only the internal energy of the ligand and the protein-ligand interaction 
energies are considered. However, the major limitation of this approach is 
that it does not include solvation and entropic effects. The approach has 
recently been extended to include protein-ligand, hydrogen-bond terms, 
for example in GOLD. 
(ii) Empirical scoring functions are derived from experimental data where the 
binding energy is estimated as the sum of localised interactions, including 
hydrogen bonds, ionic interactions, hydrophobic interactions and binding 
entropy. These functions are simpler than the force-field functions but 
they cannot be easily incorporated in new functions as they use different 
weighting factors for different terms. These functions are derived from 
molecular data by fitting and regression analysis. 
(iii) Knowledge-based scoring functions do not estimate binding energies, but 
rather attempt to reproduce experimental structures instead. Knowledge-
based scoring functions can be used for screening large compound 
libraries due to their simplicity, but they are restricted by the fact that 
they are derived from information of a limited and possibly 
unrepresentative sample of protein-ligand data. 
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6.3.1 Materials and Methods 
6.3.1 .1 Sample preparation 
A small dataset was retrieved from the ZINC database containing commercially 
available compounds. The selection was based on the following criteria: a 
substructure search of the fragment 12C05, molecular weight ≤450 Da, rotatable 
bonds less than 5, hydrogen-bond acceptor ≤ 5 and hydrogen-bond donor ≤5. 
About 1729 compounds were found to meet these criteria and were used for 
subsequent docking.  
The molecules were prepared using the software SYBYL® 8.0 provided by 
Tripos. Hydrogen atoms were added and charges assigned by the Gasteiger-
Hückel method.  
6.2.1.2 Protein preparation 
The protein structures used for this screen were derived from the high 
resolution, crystal structure analysis of the ankyrin domain with the fragment 
12C05 and a high-resolution structure for the domain defined by PDB (2F8Y). 
Hydrogen atoms were added and the protonation states were assigned according 
to the surrounding environment. The amide groups of asparagines and 
glutamines were flipped according to the most likely hydrogen-bond network. 
Histidine residues were visually inspected and tautomeric states assigned to 
allow the most favourable interactions.  
 
 6.2.1.3 The docking configuration 
Virtual screening and docking was carried out using the programme GOLD. The 
docking configuration file specifies the parameters used in the run. The amide 
bonds of the ligands were allowed to flip, protonated carboxylic acids were 
allowed to flip, non-planer sp3 nitrogens were allowed to invert, free corners of 
cyclic systems were allowed to flip above or below the plane of neighbouring 
corners, planar nitrogens bound to sp2 carbons were allowed to invert between 
the cis and trans conformations during docking. The ligand conformational space 
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was restricted by torsion angle distributions extracted from the Cambridge 
Structural Database (CSD). The docking run was terminated when the three top 
solutions were within 1.5 Å. Flexibility of the protein was achieved by applying 
soft potentials to residues TYR2075, ASP2109, ASN2040, GLU2076 LYS2079 
and  LEU2113.The functional score was GoldScore. 
 
  6.2.2 Results and discussion 
  6.2.2.1 Substructure analysis 
Substructure analysis has proved a powerful tool in high-throughput screening, 
particularly in the early stages where it can be used to analyse hit results and 
detect false-positives (Merlot et al. 2003). Substructure analysis is useful in 
toxicity prediction by avoiding known toxicophoric functional groups in the 
molecules or their metabolites (Merlot et al. 2003). Substructure search has been 
used here retrospectively after identifying compounds through the primary 
screen and identifying pharmacophoric groups crystallographically. This was 
used as another method to elaborate fragments and introduce new groups that 
could improve the binding. Compounds containing the substructure fragment 
12C05 and meeting the Lipinski rule of five of hydrogen-bond donors and 
acceptors and molecular weight were retrieved from the ZINC database library.  
A dataset library of 1729 compounds was created and these molecules were 
docked on the protein. 
 
6.2.2.2 Protein flexibility 
 
The ankyrin domain does not undergo any major conformational changes upon 
binding to the fragments or the complex as observed by the crystal structures. 
However, in reality the protein in solution is in continuous motion and this has 
been addressed by several methods as described by (Carlson & McCammon, 
2000). These methods vary in complexity and flexibility. One approach is to 
apply conformational sampling of side chains in the receptor, by either allowing 
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free rotational movements of hydrogen atoms at the receptor site or creating a 
rotameric library of side chain orientations. Another approach is by generating a 
sub-ensemble of states by Monte Carlo (MC) or Molecular dynamics (MD) 
calculations, which are reliable but slow methods. An ensemble of conformations 
can also be provided by sampling NMR structures or using multiple crystal 
structures (Carlson  & McCammon, 2000). Soft potentials were used to 
accommodate small changes in conformations. In this method, soft functions are 
allowed for some clashes between the ligand and the receptor, which has the 
advantage of a shorter calculation time. There is no distinct binding site at the 
ankyrin interface to target. Soft potentials were specified for certain residues 
surrounding the fragment 12C05 in the original crystal structure. 
 
 6.2.2.3 Choice of the target template 
Virtual screening has been a useful tool where the structure of the target protein 
has not been validated experimentally either by X-ray crystallography or NMR. 
A homology model can be used instead for screening small or large libraries 
(Kitchen et al., 2004). In fact, homology models can sometimes give better 
docking results. The choice of the crystal structure of the target would influence 
the docking results. The ideal structure to be used as a template in screening 
would be the ligand-bound protein structure as even the smallest conformational 
change could influence the docking results. The ankyrin domain structure was 
solved using X-ray crystallography at different resolutions. Docking was carried 
out using two structures: a structure solved at high resolution of 1.5 Å (PDB 
2F8Y) and a lower resolution structure of the ankyrin domain with the bound 
fragment (2.5 Å). High-resolution structures are preferred in docking for 
obtaining more reliable results. However, the high-resolution structure failed to 
reproduce the conformation of the fragment 12C05 that has been found 
experimentally. It was expected that the flexibility of the protein would have 
little effect since the ankyrin structure remains unchanged before and after 
complexation, as observed in the crystal structures. This suggested rigidity of the 
binding interface and an easier docking run. However, the crystal structures do 
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not always reflect the actual conformation in the solution state. Docking the 
fragment 12C05 is quite challenging for many reasons; one reason is the lack of 
restraints in fragment binding in small molecules as small as fragments to 
predict the correct binding mode, another reason is that most scoring functions 
have been derived for larger molecules and are not suitable for fragments. It is 
also difficult to predict the promiscuous binding mode of the fragments. The 
lower resolution structure of the ankyrin domain was used instead to screen the 
larger molecules.  
 
 6.2.2.4 Choice of scoring function 
The docking method and criteria used should be validated by using the fragment 
as a control molecule for docking. The scoring function used was GoldScore, 
which is an empirical scoring function chosen by default in the GOLD program.  
The docking result was then compared with the crystal structure of the 
fragment. The docking did not result in the exact conformation of the fragment 
but rather had an RMSD of 4.9 Å with the experimental result. Docking was 
repeated using Chemscore, another empirical fitness function, and a 1.5 Å 
resolution structure (PDB 2F8Y). However, the experiment failed again to 
reproduce the experimental conformation, resulting in an even larger RMSD of 
8.4 Å from the reference structure. The ChemScore function differs from 
GoldScore that it has been derived from measured binding affinity protein-ligand 
sets. The inability to predict the exact binding mode using the docking method 
could be attributed to lack of a significant binding pocket or the fact that the 
fragment is stacked between the two molecules in the asymmetric unit and the 
docking run included only one ankyrin molecule. The docking was repeated again 
after including a water molecule that is involved in a water-mediated 
interaction, but this did not improve the docking result and the fragment was 
reproduced at RMSD value of 6.44 Å. Some water molecules are highly conserved 
in the crystal structure and some could be important in mediating an essential 
protein-ligand interaction. There is a general rule in docking that the RSMD 
value of the re-docked structure and the reference original structure should not 
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There are different approaches to minimise the false positives caused by 
inaccurate scoring functions. One approach is docking and rescoring which is 
dependant on both the protein and the library to be screened. This would require 
using a combination of two scoring functions and finding the best combination. 
Another approach is to use consensus scoring, where top- ranked poses resulting 
from one scoring function are scored again with multiple scoring functions. The 
common compounds that are found in both are then considered for further 
experimental analysis. This method has proven useful in improving docking 
results.  However, combinations of scoring functions need to be tested and chosen 
carefully. Choosing the correct scoring function or scoring method would require 
testing the biological or binding activity of these compounds experimentally. This 
was not available, so the scoring functions were selected on the basis of a 
comparison of the docking result of the fragment 12C05 and the actual binding 
mode in the crystal structure. 
6.2.2.5 Selection of compounds 
It is important to remember that the screening and docking process does not 
accurately measure the binding energies and that it is actually an enrichment 
process that facilitates the selecting step. It helps in short-listing a larger set of 
compounds to obtain a smaller dataset that can be easily inspected visually. The 
relative ranking of those compounds in the shortlist becomes of less significance; 
compounds ranked in the top five could be as effective as those in the top 50 or 
100 lists as long as they are tested experimentally. The library of 1729 
compounds extracted from the ZINC database was not large as compared to 
HTS, which may involve thousands or even millions of compounds. However, it is 
still subjected to filtering and screening for careful analysis.  
The docking results were imported for analysis using the GoldMine software. 
Four descriptors, scored by the GoldScore function, were used to rank the 
docking results. The four descriptors were hydrogen bonds, van der Waals 
interactions, internal torsion angles and normalised fitness descriptors. Most 
scoring functions are additive resulting in higher scores for larger molecules. It is 
useful in this case to add a penalty value that is proportional to the molecular 
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weight; a normalised fitness value was used here instead. The docking results 
were filtered by using these descriptors in combination with a scoring function. 
This resulted in 34 compounds with 99 different poses as the top-ranking 
compounds. The compounds were visualised in order to examine their binding 
modes and decide on the compounds that would be tested experimentally.  
Many factors were considered in selecting the compounds: their overall score, 
their complementarity to the binding site and their commercial availability. 
Although the compounds were extracted from ZINC database which is a 
commercial source, some compounds were inaccessible and not easily available 
for testing. Two compounds were selected for further investigation. The first 
(compound 1) had the highest normalised fitness score with 2 different poses and 
ranked as first and second respectively (Table 6.2).  It has 6 rotatable bonds, logP 
is 3.73, hydrogen bond donors are 2, hydrogen bond acceptors are 5 and its 
molecular weight was 394 Da. This compound obeys the “Lipinski rule of five” 
with only one violation of the rotatable bond rule. The isoindole ring of compound 
1 is involved in an aromatic π-π interaction with the Y2075 phenyl ring. This is 
similar to the fragment 12C05, in which the phenyl ring of the fragment is 
involved in a similar interaction. The methylbutyl side chain was docked in the 
adjacent pocket and it could be involved in a hydrophobic interaction. The second 
compound (compound 2) had two poses and ranked in the 24th and 25th 
positions respectively (Table 6.3). It has a logP value of 3.77, 4 rotatable bonds, 
one hydrogen bond donor, 4 hydrogen bond acceptors and of molecular weight 
352 Da. Both compounds were purchased from Chembridge. The docked 
structure showed an aromatic π-π interaction between the isoindole ring and 
Y2075 phenyl ring as well. The furylmethyl side chain was again docked in the 
adjacent pocket. The aromatic π-π interaction was the only interaction 
reproduced in docking the two substructure compounds (Figure 6.6).  
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       [4-({[2-(3-methylbutyl)-1,3-dioxo-2,3-dihydro                          2-cyclohexyl-N-(2-furylmethyl)-
1,3-     
 -1H-isoindol-5-yl]carbonyl}amino)phenyl]acetic acid                   dioxo-5-isoindolinecarboxamide         
                           Compound 1                                                                           Compound 2 
 
 
Table 6.2 Summary of scores of compound 1 
   
 External 
HB 
External 
Vdw 
Internal 
torsion 
Normalised 
fitness 
Rank 
Pose 1 6.3137 69.673 -0.4727 0.188188    1 
Pose 2 6.9057 70.4112 -0.4668 0.188130    2 
 
Table 6.3 Summary of scores of compound 2 
 
 External HB External 
Vdw 
Internal 
torsion 
Normalised 
fitness 
Rank 
Pose1 3.8179 56.4138 -0.2255 0.1706565   24 
Pose 2 3.7001 56.5116 -0.2206 0.1705960   25 
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6.2.3 Testing compounds experimentally 
6.2.3.1 Detecting binding by Surface Plasmon resonance 
 The ankyrin domain was immobilised on a CM5 chip as it has been described in 
Chapter 5.  A series of concentrations of the two compounds was prepared by 
serial dilution. The compounds were dissolved in a PBS buffer (phosphate buffer 
pH7.5, 150 mM NaCl, 0.05% Tween 20) in 5 % DMSO. The concentration series 
included the following concentrations: 25, 12.5, 6.25, 3.125, 1.562, 0.781, 0.391, 
0.195, 0.977, 0.488, 0.244 and 0.122 mM. Solution of the compounds were 
injected onto the surface of the chip at a flow rate 30 µl/min, contact time was 60 
seconds and dissociation time was 60 seconds. A series of aliquots of PBS in 
DMSO was prepared for solvent correction as described in chapter 5. 
Regeneration was carried out by injecting 1M NaCl for 60 seconds. The run was 
carried out at a temperature 25°C.The sensorgrams were analysed using the 
Biacore T100 evaluation software and solvent correction was applied. 
 
 
6.2.3.2 Results and discussion 
Biacore has been used for screening the binding of the two compounds at various 
concentrations. The two compounds had poor solubility at higher concentrations 
but did not show any aggregation in the sensorgrams. The two compounds were 
dissolved in 5%DMSO and solvent correction was applied. Neither compounds 
showed any sign of binding and the sensorgrams returned rapidly to the baseline 
(Figure 6.7). 
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A 
 
B 
 
Figure 6.7 The sensorgrams of A) compound 1 and B) compound 2 showing no binding at a series 
of concentrations. The blank subtracted sensorgrams are solvent corrected to compensate for the 
effect of DMSO. The spikes observed mark the start and end of injection event.  
 
           
Neither of the compounds showed any binding in SPR and no electron density 
was observed in the crystal structures. Although these compounds were highly-
ranked in the docking screen, they failed to bind in experimental, solution 
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conditions. This could result from the inability of the virtual screening to predict 
the binding correctly or incorrect assignation of the protonation states of protein 
and ligands.  
The docking protocol could have been improved by optimising the docking speed 
and accuracy by setting the docking efficiency and number of genetic algorithm 
attempts to different values. Exploration of different scoring functions was found 
to be the best way forward; in these experiments the docking protocol was 
optimised initially for small fragments but probably should be re-optimised for 
larger molecules. The limited solubility of the two compounds even in 100% 
DMSO also demonstrated that this can be an obstacle and it is not considered in 
the docking screens. 
 
A major difficulty in virtual screening is its inability to identify potential 
binders. This is likely because they have been ranked poorly and disregarded 
incorrectly. Clashes with the protein receptor and other non-optimal ligand-
receptor contacts, difficulties in predicting the ionisation state of groups on the 
protein or ligand and identifying changes in ionisation on ligand binding, and 
incorrect choice of ions or water molecules could all contribute to this (Klebe, 
,2006).  
 
6.3 Summary and Conclusions 
Computational methods have become essential tools and have been integrated 
fully into drug discovery, both in high-throughput screening and in lead 
optimisation. Two different structure-based methods have been employed here to 
design larger compounds with improved binding affinity. This study was focused 
only on one fragment (12C05) that was validated both crystallographically and in 
kinetic studies.  The first approach used the software SPROUT to both link this 
fragment to another and to optimise it by building a small library of selected 
functional groups that were docked in selected sites. Some of these compounds 
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appeared unattractive for further follow-up either due to their challenging 
synthesis or to their relative lipophilicity or hydrophilicity. However, such 
compounds can still give some ideas about possible approaches for fragment 
optimisation. A major limitation of SPROUT is that it does not allow for protein 
flexibility. This could be overcome by re-docking the generated structures using 
docking programmes that allow flexibility of residues in binding sites.  
The second approach used was virtual screening, which allowed docking a small 
commercially available library to the expected binding site. The program GOLD 
was used to shortlist the compounds that were likely to bind. Only two of the 34 
compounds in the shortlist were selected for experimental validation. These did 
not show any binding when measured by SPR. The rest were not tested, so it is 
not known whether these two compounds were false-positives or whether the 
docking and screening protocol needed further optimisation. However, the 
virtual screening method is still vital in the drug design process. It does, 
nevertheless, require experimental validation to optimise the docking 
parameters, which may differ according to the protein target and the nature of 
the compounds in the library. 
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Chapter 7 
 
Conclusions and future directions 
 
7.1 Conclusions 
The Notch signalling pathway is an important conserved pathway that has 
attracted much interest over the years. The Notch receptor and ligand are 
transmembrane proteins where ligand binding induces the release of an 
intracellular domain of the Notch receptor. The intracellular domain translocates 
to the nucleus where it is involved in the formation of an active transcription 
complex with CSL and MAML. Notch signalling is involved in different 
developmental processes; and abnormalities in the expression or function of 
different components of the Notch receptor are implicated in various diseases 
and cancers. There have been several approaches to development of therapeutic 
agents that modulate Notch signalling. Targeting the downstream events 
through interfering with the formation of the transcription complex is one 
direction that could be investigated. The ankyrin domain of the Notch 
intracellular domain plays an instrumental role in formation of the active 
transcription complex. In this work, I have explored the druggability of the 
ankyrin domain using a fragment-based approach 
 
Several computational methods developed to predict druggability rely on 
geometrical and energy-based algorithms. However, many of these methods are 
incapable of predicting binding sites on protein-protein interfaces due to the lack 
of distinctive binding pockets.  
In this study, I assessed the druggability of the ankyrin domain experimentally 
by screening against a commercial library. The hit rate and nature of hits 
depend on the design of the screening library, especially the nature of the 
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chemical moieties and the chemical space that it covers. In addition, it relies on 
the screening method, including its sensitivity and its ability to distinguish false 
positives and false negatives from true binders. In this dissertation, the 
screening library included fragments that complied with the “rule of three” 
(Congreve et al., 2003). The assembly of the library was not target-specific as 
this project was part of a larger drug discovery campaign screening a wide range 
of targets. The fluorescent-based thermal shift screening assay required the 
protein to unfold in a two-state manner in order to compare unfolding in 
presence and absence of fragments. After optimisation of screening conditions, 36 
fragment hits were identified from a library of 1201 compounds giving a hit rate 
approximately 3%. The identified hits were grouped in five main classes: benzyl 
derivatives, fused bicylic rings, biaryl compounds, phenyl derivatives, and 5-
membered heterocyclic rings. Although the frequency of these hits could be a 
function of the representation of these compounds in the screening library, these 
chemical scaffolds seemed favourable to bind with the ankyrin domain. These 
small molecules are the first identified to bind to the Notch1 ankyrin domain.  
The affinities of the confirmed fragment hits were measured using Surface 
Plasmon Resonance (SPR). As expected, they were mostly in the millimolar 
range, not unusual for smaller molecules. The on- and off-rates of some 
fragments were measured after fitting a 1:1 model, but other fragments could not 
be analysed due to very fast on- and off-rates leading to a square-shaped 
sensorgram. The fragments were prioritised according to their affinity values, 
and then chemically optimised in order to improve their binding affinities. The 
lack of improvement led to the conclusion that the initial hits were the most 
favourable chemical scaffolds for binding the ankyrin domain.  
The binding mode of the fragment hits was then investigated using X-
crystallography. A small subset of two fragments, 12C05 and 9F07, was 
identified binding in the crystal structures. Probably owing to their very weak 
binding affinities, low occupancies and very fast off-rates, other fragments were 
not visible in the electron density maps. However, the two successful fragment-
bound structures gave interesting insights into how small molecules can bind to 
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the ankyrin domain. Although it was expected that the fragments would bind in 
the concave region formed by the ankyrin-repeat architecture, they were found to 
bind residues in the upper helices involved in protein-protein interactions. This 
strongly suggests the possibility of mimicking protein-protein interactions by 
small molecules at the ankyrin interaction interface. However, elaborating the 
fragments and developing them to potential inhibitors is likely to be quite 
challenging given the flat surface and lack of anchoring small cavities adjacent 
to the two fragments.   
Computational tools were employed to grow and link the two fragments together. 
A docking programme (GOLD) and de novo drug design software (SPROUT) 
assisted in finding and designing larger compounds based on the original scaffold 
of the fragment 12C05. Two compounds were selected and were tested 
experimentally but did not show any binding. However, these two compounds do 
not represent the complete docking output and other compounds need to be 
tested. 
 
 7.2 Lessons learnt for future directions 
Choice of target 
 On embarking on a drug discovery program it is important to choose the target 
carefully.The first criterion to consider is the the biology and function of the 
target and how closely it is linked to the human disease. The availability and the 
ability to express and produce the target protein in a reproducible fashion 
becomes an essential requirement for a highly iterative process. In addition, the 
presence of well-defined pockets is usually assessed to identify the druggability 
of the target. The ankyrin domain is a good example of a protein whose biological 
function is well understood and its involvement in progression of T-ALL is 
characterised. However, the druggability of a protein fold comprising ankyrin 
repeats had not been investigated before. The results shown here indicate that it 
is possible to target the Notch1 ankyrin domain with small molecules, although 
optimisation of these molecules remains challenging. The ankyrin repeat is a 
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scaffold that mediates many protein-protein interactions and the discovery of 
small molecules that could bind and inhibit these interactions of wide interest for 
a number of different therapeutic interventions.  
           
7.3 Future directions:  
7.3.1 Choice of Target 
Progress in targeting the ankyrin domain using a fragment-based approach has 
been encouraging and could be beneficial to inhibition of the formation of the 
active Notch transcription complex. However, in view of the fact that the ankyrin 
domain binds first with CSL and then MAML is recruited to stabilise the 
complex, the ankyrin-CSL binary complex might alternatively be used as a 
target to screen small molecules that either stabilise or destabilise the 
transcription complex.  
7.3.2 Library design 
Fragment libraries cover a larger chemical space and are easier to assemble and 
synthesise than HTS libraries. The relatively high hit rate that was shown by 
initial screening of the ankyrin domain suggests that the fragment-based 
approach could be a successful alternative for targeting protein-protein 
interactions. However, the hit rate could always be improved by designing a 
more tailored and target-specific library. Enriching the library with molecules 
similar to amino acids might enhance the success rates for difficult protein-
protein interfaces. Although the physical properties are governed by the “rule of 
three” that restricts the choice of fragments, fragment solubility is particularly 
important for technical and practical reasons. As has been shown here with the 
ankyrin domain, solubility of fragments was a limiting factor for hit 
identification, kinetic characterisation of fragment hits and protein-ligand 
crystallisation attempts. It is arguable that fragments are hydrophobic small 
molecules and improving solubility could be achieved at later optimisation 
stages. However, hit-to-lead progression starts by identifying and prioritising the 
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most promising initial molecules that could be missed in early screening due to 
solubility problems. 
A more focused library could be designed based on the confirmed hits that were 
found. Elimination of any functional groups that would destabilise the protein 
such as the carboxylic and trifluoromethyl groups and investigating a broader 
chemical space would help in enhancing the hit rates and exploring different 
scaffolds that could be more favourable and more potent for binding. 
 
7.3.3 Fragment Screening  
Orthogonal screening can confirm initial hits by testing the compounds using 
two different methods. The screening of the ankyrin domain was carried out 
using a thermal-based shift assay that has proved to be a successful screening 
approach to hit identification. The positive hits were then confirmed by SPR for 
kinetic and affinity measurements. However, different screening methods with 
different sensitivities could lead to different outputs, especially when different 
methods require particular screening conditions such as buffer composition and 
temperature. The mismatch of screening conditions could result in hit variations 
from one method to another, so careful assessment of the quality of hits by each 
method is necessary. Publications usually list the positive hits, discarding 
negative molecules that either do not bind or are regarded as promiscuous. Such 
information is useful when it comes to designing target-specific libraries by 
understanding which chemical moieties should be avoided. Screening the 
ankyrin domain using the thermal-shift assay has detected compounds that 
destabilise the protein by reducing its melting point. These compounds contained 
certain functional groups that could be avoided in future tailored libraries or 
during hit-to-lead optimisation. In addition, in case of difficult drug targets it is 
important to be able to distinguish if the hit-rate is a true representation of the 
druggability of target or due to technical and optimisation difficulties of the 
screening method itself.  
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Three biophysical methods were used here for screening and testing the binding 
of fragments to the ankyrin domain: fluorescent-based thermal shift assay, SPR 
and X-ray crystallography. Other complementary methods could be employed, 
such as heteronuclear NMR-based screening, which has very low false-positive 
and false-negative rates, and is able to identify new and different scaffolds. 
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